[go: up one dir, main page]

EP1786802A1 - Pyrimidinylimidazoles as tgf-beta inhibitors - Google Patents

Pyrimidinylimidazoles as tgf-beta inhibitors

Info

Publication number
EP1786802A1
EP1786802A1 EP05789340A EP05789340A EP1786802A1 EP 1786802 A1 EP1786802 A1 EP 1786802A1 EP 05789340 A EP05789340 A EP 05789340A EP 05789340 A EP05789340 A EP 05789340A EP 1786802 A1 EP1786802 A1 EP 1786802A1
Authority
EP
European Patent Office
Prior art keywords
bicyclo
imidazol
pyrimidin
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05789340A
Other languages
German (de)
French (fr)
Inventor
Wen-Cherng Lee
Lihong Sun
Claudio Chuaqui
Juswinder Singh
Feng Shan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35431931&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1786802(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc, Biogen Idec MA Inc filed Critical Biogen Idec Inc
Publication of EP1786802A1 publication Critical patent/EP1786802A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

  • TGF/3 Transforming Growth Factor /3 is a member of a large family of dimeric polypeptide growth factors that includes, for example, activins, inhibins, bone morphogenetic proteins (BMPs), growth and differentiation factors (GDFs) and mullerian inhibiting substance (MIS).
  • BMPs bone morphogenetic proteins
  • GDFs growth and differentiation factors
  • MIS mullerian inhibiting substance
  • TGF/3 exists in three isoforms (TGF/31, TGF/32, and TGF/33) and is present in most cells, along with its receptors. Each isoform is expressed in both a tissue-specific and developmentally regulated fashion.
  • Each TGF/3 isoform is synthesized as a precursor protein that is cleaved intracellularly into a C-terminal region (latency associated peptide (LAP)) and an N-terminal region known as mature or active TGF/3.
  • LAP latency associated peptide
  • LAP is typically non-covalently associated with mature TGF/3 prior to secretion from the cell.
  • the LAP-TGF/3 complex cannot bind to the TGF ' ⁇ receptors and is not biologically active.
  • TGF ⁇ is generally released (and activated) from the complex by a variety of mechanisms including, for example, interaction with thrombospondin-1 or plasmin.
  • TGF/3 binds at high affinity to the type II receptor (TGF/3RII), a constitutively active serine/threonine kinase.
  • TGF/3RII type II receptor
  • the ligand-bound type II receptor phosphorylates the TGF/3 type I receptor (AIk 5) in a glycine/serine rich domain, which allows the type I receptor to recruit and phosphorylate downstream signaling molecules, Smad2 or Smad3.
  • TGF/3RII type II receptor
  • AIk5 TGF/3 type I receptor
  • Phosphorylated Smad2 or Smad3 can then complex with Smad4, and the entire hetero-Smad complex translocates to the nucleus and regulates transcription of various TGF/3-responsive genes. See, e.g., Massague, J. Ann. Rev .Biochem. Med. 67: 773 (1998).
  • Activins are also members of the TGF/3 superfamily, which are distinct from TGF/3 in that they are homo- or heterodimers of activin /3a or /3b. Activins signal in a manner similar to TGF/3 , that is, by binding to a constitutive serine-threonine receptor kinase, activin type II receptor (ActRIIB), and activating a type I serine-threonine receptor, AIk 4, to phosphorylate Smad2 or Smad3. The consequent formation of a hetero-Smad complex with Smad4 also results in the activin-induced regulation of gene transcription.
  • TGF/3 and related factors such as activin regulate a large array of cellular processes, e.g., cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, inflammatory cell recruitment, immunosuppression, wound healing, and extracellular matrix production.
  • cellular processes e.g., cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, inflammatory cell recruitment, immunosuppression, wound healing, and extracellular matrix production.
  • TGFjS signaling pathway underlies many human disorders (e.g., excess deposition of extracellular matrix, an abnormally high level of inflammatory responses, fibrotic disorders, and progressive cancers).
  • activin signaling and overexpression of activin is linked to pathological disorders that involve extracellular matrix accumulation and fibrosis (see, e.g., Matsuse, T. et al., Am. J. Respir. Cell MoI. Biol. 13: 17-24 (1995); Inoue, S. et al., Biochem. Biophys. Res. Comm. 205: 441-448 (1994); Matsuse, T. et ⁇ , Am. J.
  • Pathol. 148 707- 713 (1996); De Bleser et al., Hepatology 26: 905-912 (1997); Pawlowski, J.E., et al., J. Clin. Invest. 100: 639-648 (1997); Sugiyama, M. et al., Gastroenterology 114: 550-558 (1998); Munz, B. et al., EMBOJ. 18: 5205-5215 (1999)), inflammatory responses (see, e.g., Rosendahl, A. et al., Am. J. Repir. Cell MoI. Biol. 25: 60-68 (2001)), cachexia or wasting (see Matzuk, M. M.
  • TGF ⁇ and activin can act synergistically to induce extracellular matrix production (see, e.g., Sugiyama, M. et al., Gastroenterology 114: 550-558, (1998)). It is therefore desirable to develop modulators (e.g., antagonists) to members of the TGFjS family to prevent and/or treat disorders involving this signaling pathway.
  • modulators e.g., antagonists
  • the invention is based on the discovery that compounds of formula (I) are unexpectedly potent antagonists of the TGF ⁇ family type I receptors, Alk5 and/or AIk 4.
  • compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGFjS family signaling activity is desirable.
  • fibrosis e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis
  • progressive cancers e.g., hepatic fibrosis
  • Each R a can be alkyl, alkenyl, alkynyl, alkoxy, acyl, halo, hydroxy, amino, nitro, oxo, thioxo, cyano, guanadino, amidino, carboxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkoxycarbonyl, alkylcarbonyloxy, urea, thiourea, sulfamoyl, sulfamide, carbamoyl, cycloalkyl, cycloalkyloxy, cycloalkylsulf
  • X can be cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or a bond.
  • Y can be a bond, -C(O)-, -C(O)-O-, -O-C(O)-, -S(O) P -O-, -O-S(O) P -, -C(O)-N(R b )-, -N(R b )-C(O)-, -O-C(O)-N(R b )-, -N(R b )-C(O)-O-, -C(O)-N(R b )-O-, -O-N(R b )-C(O)-, -O-S(O) p -N(R b )-, -N(R b )-S(O) p -N(R b )-, -N(R b )
  • R b and R c independently, can be hydrogen, hydroxy, alkyl, alkoxy, amino, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroaralkyl.
  • p can be 1 or 2
  • q can be 1-4.
  • R 2 can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, aralkyl, arylalkenyl, heterocycloalkyl, (heterocycloalkyl)alkyl, heterocycloalkenyl, (heterocycloalkenyl)alkyl, heteroaryl, heteroaralkyl, or (heteroaryl)alkenyl.
  • Each of A 1 and A 2 independently, can be N or NR b .
  • a 1 is NR b
  • a 2 is N, and vice versa.
  • the variable, m can be 0, 1, 2, or 3.
  • the pyrimidinyl ring cari be unsubstituted or substituted with 1-3 R a groups. Note that when m >2, two adjacent R a groups can join together to form a 4- to 8-membered optionally substituted cyclic moiety.
  • the pyrimidinyl ring can fuse with a cyclic moiety to form a moiety, that can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, heteroaryl, aryloxy, heteroaryloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylthio, sulfoxy, sulfamoyl, oxo, or carbamoyl.
  • substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as
  • X can be aryl or heteroaryl.
  • X can be an optionally substituted phenyl (e.g., alkyl or cyano).
  • Y can be a bond, -N(R b )-C(O)-, -N(R b )-S(O) 2 -, -C(O)-, -C(O)-O-, -0-C(O)-, -C(O)-N(R b )-, -S(OV, -O", -S(O) 2 -N(R b )-, - N(R b )-, -N(R b )-C(O)-O-, -N(R b )-C(O)-N(R c )-, -C(O)-N(R b )-S(O) p -N(R c )-, or -C(O)
  • R 2 can be hydrogen, Ci -6 alkyl, aryl, heteroaryl, aryl-Ci ⁇ alkyl, or heteroaryl-C ⁇ alkyl.
  • X can be a 4- to 8-membered monocyclic cycloalkyl or heterocycloalkyl, or X can be a 4- to 8-membered bicyclic cycloalkyl or heterocycloalkyl.
  • X can be piperidinyl, piperazinyl, pyrrolidinyl, tetrahydrofuran, cyclohexyl, cyclopentyl, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.1]octane, 2-oxa-bicyclo[2.2.2]octane, 2-aza-bicyclo[2.2.2]octane, 3-aza-bicyclo[3.2.1]octane, or 1 -aza-bicyclo[2.2.2]octane.
  • X can be piperidinyl, piperazinyl, or pyrrolidinyl.
  • the piperdinyl, piperazinyl, or pyrrolidinyl can be bonded to Y via its nitrogen ring atom.
  • Y can be a bond, -C(O)O-, -C(O)-N(R b )-, -S(O) 2 -, or -S(O) 2 -N(R* 3 )-, wherein R b is hydrogen or C M alkyl.
  • X can be cyclohexyl, cyclopentyl, or bicyclo[2.2.2]octane
  • Y can be -N(R b )-C(O)-, -N(R b )-S(O) 2 -, -C(O)-, -C(O)-O-, -0-C(O)-, -C(O)-N(R b )-, -S(OV, -O-, -S(O) 2 -N(R b )-, - N(R b )-, -N(R b )-C(0)-0-, -C(O)-N(R b )-O-, or -N(R b )-C(O)-N(R c )-.
  • Y can be -N(R b )-C(0)-, -N(R b )-S(O) 2 -, -C(O)-, -C(O)-O-, -0-C(O)-, -C(O)-N(R b )-, -S(OV, -O-, -S(O) 2 -N(R b )-, - N(R b )-, -N(R b )-C(O)-O-, -C(O)-N(R b )-O-, -N(R b )-C(0)-N(R c )-, -C(O)-N(R b )-S(O) p -N(R c )-, or -C(O)-O-S(O) p -N(R b )-.
  • X and Y are each a bond;
  • R 2 can be hydrogen or C 1-6 alkyl (e.g., Ci -4 alkyl such as methyl or t-butyl);
  • m can be 1 or 2 (e.g., m can be 1);
  • at least one R a is substituted at the 2-pyrimidinyl position and this R a can be Ci -4 alkyl, C 3-6 cycloalkyl, or amino (e.g, -CH 3 , - CF 3 , cyclopropyl, -NH 2 , -NH-C 1-4 alkyl, or -NH-cycloalkyl such as -NH-cyclopropyl).
  • R 2 can be hydrogen, C 1-6 alkyl, aryl, heteroaryl, aryl-Ci ⁇ alkyl, or heteroaryl-Ci- 4 alkyl.
  • R 2 can be hydrogen, Ci -4 alkyl, phenyl, pyridyl, imidazolyl, furanyl, thienyl, triazolyl, tetrazolyl, benzyl, phenylethyl, benzimidazolyl, benzothiazolyl, naphthylmethyl, naphthylethyl, or -Ci -2 alkyl-pyridyl; each of which, independently, is optionally substituted with one or more substituents selected from the group consisting of fluoro, chloro, trifluoromethyl, methyl, ethyl, aminocarbonyl, alkylcarbonylamino, sulfamoyl, alkoxycarbonyl, and alkylcarbony
  • R " can be hydrogen, methyl, ethyl, n-butyl, t-butyl, benzyl or pyridylmethyl.
  • R 2 can be hydrogen, hydroxymethyl, or trifluoromethyl.
  • R 1 can be benzo[l,3]dioxolyl, benzo[ ⁇ ]thiophenyl, benzo-oxadiazolyl, benzothiadiazolyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl,
  • m can be 0-2.
  • R a can be substituted at the 2-pyrimidinyl position.
  • R a can be C 1-4 alkyl, C 1-4 alkoxy, Ci -4 alkylthio, halo, amino, aminocarbonyl, or alkoxycarbonyl.
  • a 1 can be N and A 2 is NR b , or A 1 is NR b and A 2 is N; wherein R b is hydrogen or Ci -4 alkyl.
  • m can be 0-2;
  • R 1 can be heteroaryl;
  • R 2 can be hydrogen, C 1 ⁇ alkyl, aryl, heteroaryl, -Ci -4 alkyl-aryl, Or -Ci -4 alkyl-heteroaryl;
  • X can be a 4- to 8-membered monocyclic or bicyclic cycloalkyl or heterocycloalkyl; and
  • Y can be -N(R b )-C(O)-,
  • m can be 0-2;
  • R 1 can be heteroaryl;
  • R 2 can be hydrogen, Ci -6 alkyl, aryl, heteroaryl, -Ci -4 alkyl-aryl, or -Ci -4 alkyl-heteroaryl;
  • X can be piperidinyl, piperazinyl, pyrrolidinyl, tetrahydrofuran, cyclohexyl, cyclopentyl, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.1]octane, 2-oxa-bicyclo[2.2.2]octane,
  • Y can be -N(R b )-C(O)-, -N(R b )-S(O) 2 -, -C(O)-, -C(O)-O-, -0-C(O)-, -C(O)-N(R b )-, -S(O) P -, -O-,
  • m can be 0-2;
  • R 1 can be heteroaryl;
  • R 2 can be hydrogen, Ci -6 alkyl, aryl, heteroaryl, -Ci -4 alkyl-aryl, Or -Ci -4 alkyl-heteroaryl; and
  • -X-Y- can be
  • a 1 can be N and A 2 can be NH.
  • a 1 can be NH and A 2 can be N.
  • R 2 can be hydrogen, Ci -4 alkyl, benzyl, or pyridylmethyl; m can be 1 and R a can be substituted at the 2-pyrimidinyl position.
  • m can be 0-2;
  • R 1 can be heteroaryl;
  • R 2 can be hydrogen, Ci -6 alkyl, aryl, heteroaryl, aryl-Ci ⁇ alkyl, or heteroaryl-C M alkyl;
  • X can be cyclohexyl, cyclopentyl, or bicyclo[2.2.2]octane;
  • Y can be -N(R b )-C(0)-, -N(R b )-S(O) 2 -, -C(O)-, -C(O)-O-, -0-C(O)-,
  • R b and R c independently, can be hydrogen or Ci -4 alkyl.
  • a 1 can be N and A 2 can be NH, or alternatively, A 1 can be NH and A 2 can be N.
  • R 2 can be hydrogen, Ci -4 alkyl, benzyl, or pyridylmethyl; m can be 1 and R a can be substituted at the 2-pyrimindyl position.
  • X and Y can each be a bond;
  • R 2 can be hydrogen or Ci -4 alkyl;
  • m can be 1;
  • R a can be -CH 3 , -CF 3 , cyclopropyl, -NH 2 , -NH-Ci -4 alkyl, or -NH-cycloalkyl;
  • R 1 can be benzo[l,3]dioxolyl, benzo[6]thiophenyl, benzooxadiazolyl, benzothiadiazolyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, 2-oxo-benzooxazolyl, pyridyl, pyrimidinyl,
  • the compound of formula (I) can be:
  • a pharmaceutical composition includes a compound of formula (I) and a pharmaceutically acceptable carrier.
  • a method of inhibiting the TGF/3 signaling pathway in a subject includes administering to said subject an effective amount of a compound of formula (I).
  • a method of inhibiting the TGF/3 type I receptor in a cell includes contacting said cell with an effective amount of a compound of formula (I).
  • a method of reducing the accumulation of excess extracellular matrix induced by TGF/3 in a subject includes administering to said subject an effective amount of a compound of formula (I).
  • a method of treating or preventing fibrotic condition in a subject includes administering to said subject an effective amount of a compound of formula (I).
  • the fibrotic condition can be, for example, scleroderma, lupus nephritis, connective tissue disease, wound healing, surgical scarring, spinal cord injury, CNS scarring, acute lung injury, pulmonary fibrosis (such as idiopathic pulmonary fibrosis), chronic obstructive pulmonary disease, adult respiratory distress syndrome, drug-induced lung injury, glomerulonephritis, diabetic nephropathy, hypertension-induced nephropathy, alimentary track or gastrointestinal fibrosis, renal fibrosis, hepatic or biliary fibrosis (such as liver cirrhosis, primary biliary cirrhosis, fatty liver disease, primary sclerosing cholangitis), restenosis, cardiac fibrosis, opthalmic scarring, fibrosclerosis,
  • a method of inhibiting growth or metastasis of tumor cells and/or cancers in a subject includes administering to said subject an effective amount of a compound of formula (I).
  • a method of treating a disease or disorder mediated by an overexpression of TGF ⁇ includes administering to a subject in need of such treatment an effective amount of a compound of formula (I).
  • the disease or disorder can be, for example, demyelination of neurons in multiple sclerosis, Alzheimer's disease, cerebral angiopathy, squamous cell carcinomas, multiple myeloma, melanoma, glioma, glioblastomas, leukemia, sarcomas, leiomyomas, mesothelioma, or carcinomas of the lung, breast, ovary, cervix, liver, biliary tract, gastrointestinal tract, pancreas, prostate, and head and neck.
  • N-oxide derivative or a pharmaceutically acceptable salt of each of the compounds of formula (I) is also within the scope of this invention.
  • a nitrogen ring atom of the imidazole core ring or a nitrogen-containing heterocyclyl substituent can form an oxide in the presence of a suitable oxidizing agent such as m-chloroperbenzoic acid or H 2 O 2 .
  • a compound of formula (I) that is acidic in nature e.g., having a carboxyl or phenolic hydroxyl group
  • a pharmaceutically acceptable salt such as a sodium, potassium, calcium, or gold salt.
  • salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, and ⁇ -methylglycamine.
  • a compound of formula (I) can be treated with an acid to form acid addition salts.
  • acids examples include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, methanesulfonic acid, phosphoric acid,/>-bromophenyl-sulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, oxalic acid, malonic acid, salicylic acid, malic acid, fumaric acid, ascorbic acid, maleic acid, acetic acid, and other mineral and organic acids well known to those skilled in the art.
  • the acid addition salts can be prepared by treating a compound of formula (I) in its free base form with a sufficient amount of an acid (e.g., hydrochloric acid) to produce an acid addition salt (e.g., a hydrochloride salt).
  • the acid addition salt can be converted back to its free base form by treating the salt with a suitable dilute aqueous basic solution (e.g., sodium hydroxide, sodium bicarbonate, potassium carbonate, or ammonia).
  • a suitable dilute aqueous basic solution e.g., sodium hydroxide, sodium bicarbonate, potassium carbonate, or ammonia.
  • Compounds of formula (1) can also be, e.g., in a form of achiral compounds, racemic mixtures, optically active compounds, pure diastereomers, or a mixture of diastereomers.
  • Compounds of formula (I) exhibit surprisingly high affinity to the TGF/3 family type I receptors, AIk 5 and/or AIk 4, e.g., with ICs 0 and Kj values of less than 10 ⁇ M under conditions as described below in Examples 34 and 36, respectively.
  • Some compounds of formula (I) exhibit IC5 0 and K; values of less than 1 ⁇ M (such as below 50 nM).
  • Compounds of formula (I) can also be modified by appending appropriate functionalities to enhance selective biological properties.
  • modifications are known in the art and include those that increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism, and/or alter rate of excretion. Examples of these modifications include, but are not limited to, esterif ⁇ cation with polyethylene glycols, derivatization with pivolates or fatty acid substituents, conversion to carbamates, hydroxylation of aromatic rings, and heteroatom-substitution in aromatic rings.
  • the present invention also features a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) (or a combination of two or more compounds of formula (I)) and at least one pharmaceutically acceptable carrier.
  • a medicament composition including any of the compounds of formula (I), alone or in a combination, together with a suitable excipient.
  • the invention also features a method of inhibiting the TGF/3 family type I receptors, AIk 5 and/or AIk 4 (e.g., with an IC 50 value of less than 10 ⁇ M; such as, less than 1 ⁇ M; and for example, less than 5 nM) in a cell, including the step of contacting the cell with an effective amount of one or more compounds of formula (I). Also within the scope of the invention is a method of inihibiting the TGF/3 and/or activin signaling pathway in a cell or in a subject (e.g., a mammal such as a human), including the step of contacting the cell with or administering to the subject an effective amount of one or more of the compounds of formula (I).
  • a subject e.g., a mammal such as a human
  • Also within the scope of the present invention is a method of treating a subject or preventing a subject from suffering a condition characterized by or resulted from an elevated level of TGF/3 and/or activin activity.
  • the method includes the step of administering to the subject an effective amount of one or more of a compound of formula (I).
  • the conditions include an accumulation of excess extracellular matrix; a fibrotic condition (which can be induced by drug or radiation), e.g., scleroderma, lupus nephritis, connective tissue disease, wound healing, surgical scarring, spinal cord injury, CNS scarring, acute lung injury, pulmonary fibrosis (such as idiopathic pulmonary fibrosis and radiation-induced pulmonary fibrosis), chronic obstructive pulmonary disease, adult respiratory distress syndrome, acute lung injury, drug-induced lung injury, glomerulonephritis, diabetic nephropathy, hypertension-induced nephropathy, alimentary track or gastrointestinal fibrosis, renal fibrosis, hepatic or biliary fibrosis, liver cirrhosis, primary biliary cirrhosis, cirrhosis due to fatty liver disease (alcoholic and nonalcoholic steatosis), primary sclerosing cholangitis, restenosis, cardiac fibrosis
  • an "alkyl” group refers to a saturated aliphatic hydrocarbon group containing 1-8 (e.g., 1-6 or 1-4) carbon atoms.
  • An alkyl group can be straight or branched. Examples of an alkyl group include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-heptyl, and 2-ethylhexyl.
  • An alkyl group can be optionally substituted with one or more substituents such as alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, amino, nitro, carboxy, cyano, halo, hydroxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, cycloalkyl-alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, heterocycloalkyl-carbonylamino, heterocycloalkyl- alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, urea, thiourea, sulfamoyl,
  • an "alkenyl” group refers to an aliphatic carbon group that contains 2-8 (e.g., 2-6 or 2-4) carbon atoms and at least one double bond. Like an alkyl group, an alkenyl group can be straight or branched. Examples of an alkenyl group include, but are not limited to, allyl, isoprenyl, 2-butenyl, and 2-hexenyl.
  • An alkenyl group can be optionally substituted with one or more substituents such as alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, amino, nitro, carboxy, cyano, halo, hydroxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, cycloalkyl-alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, heterocycloalkyl-carbonylamino, heterocycloalkyl-alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, urea, thiourea, sulfamoyl,
  • an "alkynyl” group refers to an aliphatic carbon group that contains 2-8 (e.g., 2-6 or 2-4) carbon atoms and has at least one triple bond.
  • An alkynyl group can be straight or branched. Examples of an alkynyl group include, but are not limited to, propargyl and butynyl.
  • An alkynyl group can be optionally substituted with one or more substituents such as alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, amino, nitro, carboxy, cyano, halo, hydroxy, sulfo, mercapto, alkylsulfanyl, alkylsulfmyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, cycloalkyl-alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, heterocycloalkyl- carbonylamino, heterocycloalkyl-alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, urea, thiourea, sulfamoyl,
  • an “amino” group refers to -NR X R Y wherein each of R x and R ⁇ is independently hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, aryl, aralkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, heteroaryl, or heteroaralkyl.
  • R x has the same meaning as defined above.
  • an "aryl” group refers to phenyl, naphthyl, or a benzofused group having 2 to 3 rings.
  • a benzofused group includes phenyl fused with one or two C 4-8 carbocyclic moieties, e.g., 1, 2, 3, 4-tetrahydronaphthyl, indanyl, or fluorenyl.
  • An aryl is optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkyl)alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloal
  • an "aralkyl” group refers to an alkyl group (e.g., a C 1-4 alkyl group) that is substituted with an aryl group. Both “alkyl” and “aryl” have been defined above. An example of an aralkyl group is benzyl.
  • a "cycloalkyl” group refers to an aliphatic carbocyclic ring of 3-10 (e.g., 4-8) carbon atoms.
  • Examples of cycloalkyl groups include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, norbornyl, cubyl, octahydro-indenyl, decahydro-naphthyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, and bicyclo[3.2.3]nonyl.
  • a "cycloalkenyl” group refers to a non-aromatic carbocyclic ring of 3-10 (e.g., 4- 8) carbon atoms having one or more double bond.
  • Examples of cycloalkenyl groups include cyclopentenyl, 1,4-cyclohexa-di-enyl, cycloheptenyl, cyclooctenyl, hexahydro-indenyl, octahydro-naphthyl, bicyclo[2.2.2]octenyl, and bicyclo[3.3.1]nonenyl.
  • a cycloalkyl or cycloalkenyl group can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkyl)alkylcarbonylamino, arylcarbonylamino, aralkyl
  • heterocycloalkyl refers to a 3- to 10-membered (e.g., 4- to 8- membered) saturated ring structure, in which one or more of the ring atoms is a heteroatom, e.g., N, O, or S.
  • heterocycloalkyl group examples include piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrofuryl, dioxolanyl, oxazolidinyl, isooxazolidinyl, morpholinyl, octahydro-benzofuryl, octahydro-chromenyl, octahydro-thiochromenyl, octahydro-indolyl, octahydro-pyrindinyl, decahydro-quinolinyl, octahydro-benzo[Z>]thiophenyl, 2-oxa- bicyclo[2.2.2]octyl, l-aza-bicyclo[2.2.2]octyl, 3-aza-bicyclo[3.2.1]octyl, anad 2,6-dioxa- tricyclo[3.3.1.0 3 ' 7 ]non
  • heterocycloalkenyl group refers to a 3- to 10- membered (e.g., 4- to 8-membered) non-aromatic ring structure having one or more double bonds, and wherein one or more of the ring atoms is a heteroatom, e.g., N, O, or S.
  • a heterocycloalkyl or heterocycloalkenyl group can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalky ⁇ alkylcarbonylamino, arylcarbonylamino, aralkylcarbon
  • a "heteroaryl” group refers to a monocyclic, bicyclic, or tricyclic ring structure having 5 to 15 ring atoms wherein one or more of the ring atoms is a heteroatom, e.g.,
  • heteroaryl examples include pyridyl, furyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, indolyl, tetrazolyl, benzofuryl, benzthiazolyl, xanthene, thioxanthene, phenothiazine, dihydroindole, and benzo[l,3]dioxole.
  • a heteroaryl is optionally substituted with one or more substiruents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl,
  • heterocycloalkyl alkyl
  • aryl, heteroaryl alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkyl)alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkyl)alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea,
  • heteroarylkyl group refers to an alkyl group (e.g., a C M alkyl group) that is substituted with a heteroaryl group. Both “alkyl” and “heteroaryl” have been defined above.
  • cyclic moiety includes cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, or heteroaryl, each of which has been defined previously.
  • a "carbamoyl” group refers to a group having the structure -O-CO-
  • NR x R y or -NR X -CO-O-R Z wherein R x and R y have been defined above and R z can be alkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroaralkyl.
  • a "carboxy” and a “sulfo” group refer to -COOH and -SO 3 H, respectively.
  • alkoxy refers to an alkyl-O- group where “alkyl” has been defined previously.
  • a "sulfoxy" group refers to -O-SO-R X or -SO-O-R X , where R x has been defined above.
  • halogen or halo group refers to fluorine, chlorine, bromine or iodine.
  • a "sulfamoyl” group refers to the structure -S(O) 2 -NR x R y or -NR X - S(O) 2 -R 2 wherein R x , R y , and R z have been defined above.
  • sulfamide refers to the structure -NR X -S(O) 2 -NR Y R Z wherein R x , R ⁇ , and R z have been defined above.
  • a "urea” group refers to the structure -NR X -CO-NR Y R Z and a “thiourea” group refers to the structure -NR X -CS-NR Y R Z .
  • R x , R ⁇ , and R z have been defined above.
  • an effective amount is defined as the amount required to confer a therapeutic effect on the treated patient, and is typically determined based on age, surface area, weight, and condition of the patient. The interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich et al., Cancer Chemother. Rep., 50: 219 (1966).
  • Body surface area may be approximately determined from height and weight of the patient. See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardsley, New York, 537 (1970).
  • patient refers to a mammal, including a human.
  • An antagonist as used herein, is a molecule that binds to the receptor without activating the receptor. It competes with the endogenous ligand(s) or substrate(s) for binding site(s) on the receptor and, thus inhibits the ability of the receptor to transduce an intracellular signal in response to endogenous ligand binding.
  • compounds of formula (I) are antagonists of TGF/3 receptor type I (Alk5) and/or activin receptor type I (Alk4), these compounds are useful in inhibiting the consequences of TGF/3 and/or activin signal transduction such as the production of extracellular matrix (e.g., collagen and fibronectin), the differentiation of stromal cells to myofibroblasts, and the stimulation of and migration of inflammatory cells.
  • TGF/3 receptor type I Alk5
  • activin receptor type I Alk4
  • these compounds of formula (I) inhibit pathological inflammatory and fibrotic responses and possess the therapeutic utility of treating and/or preventing disorders or diseases for which reduction of TGF/3 and/or activin activity is desirable (e.g., various types of fibrosis or progressive cancers).
  • the compounds of formula (I) are useful for studying and researching the role of TGFjS receptor type I (Alk5) and/or activin receptor type I (Alk4), such as their role in cellular processes, for example, signal transduction, production of extracellular matrix, the differentiation of stromal cells to myofibroblasts, and the stimulation of and migration of inflammatory cells.
  • TGFjS receptor type I Alk5
  • activin receptor type I Alk4
  • the compounds of formula (I) are useful for studying and researching the role of TGFjS receptor type I (Alk5) and/or activin receptor type I (Alk4), such as their role in cellular processes, for example, signal transduction, production of extracellular matrix, the differentiation of stromal cells to myofibroblasts, and the stimulation of and migration of inflammatory cells.
  • the invention features compounds of formula (I), which exhibit surprisingly high affinitiy for the TGF ⁇ family type I receptors, AIk 5 and/or AIk 4. Synthesis of the Compounds of formula (I)
  • Compounds of formula (I) may be prepared by a number of known methods from commercially available or known starting materials.
  • compounds of formula (I) are prepared according to Schemes Ia, Ib, or Ic below.
  • optionally substituted 2-methylpyrimidine (II) is deprotonated by LDA before reacting with R 1 -substituted carboxylic acid methoxy-methyl-amide (V) to form an R 1 -(6-methylpyrimidinyl)-ketone (III).
  • R 1 has been defined above.
  • the methoxy-methyl-amide can be prepared by reacting a corresponding acid chloride (i.e., R'-CO-CI) with N, 0-dimethylhydroxylamine hydrochloride.
  • R'-CO-CI acid chloride
  • the R 1 -(6-methylpyrimidinyl)-ketone (III) can then be treated with sodium nitrite in acetic acid to afford an ⁇ -keto-oxime (IV), which can undergo further reaction with an appropriate substituted (and optionally protected) aldehyde (VI) in the presence of ammonium acetate to yield a compound of formula (I).
  • the above-described compounds of formula (I) can be prepared according to Scheme Ib below. Specifically, l,l-dimethoxy-propan-2-one can first react with dimethoxymethyl-dimethyl-amine at an elevated temperature to produce the intermediate 4- dimethylamino-l,l-dimethoxy-but-3-en-2-one, which can then react with an R a -substituted amidine to form an R a -substituted pyrimidine-2-carbaldehyde (Ila).
  • This carbaldehyde (Ha) can then reacted with aniline and diphenyl phosphite to form a resulting N.P-acetal, which can further couple with an R 1 -substituted aldehyde to produced an (R'-methyty-pyrirnidinyl-ketone ( ⁇ ia). See, e.g., Journet et al., Tetrahedron Lett 39: 1717-1720 (1998).
  • a compound of formula (I) can be prepared by reacting intermediate (IV) or (FVa) with an aldehyde (VII) to yield a further intermediate (VIII), which can then react with compound (IX) to yield a compound of formula (I).
  • moieties Y' and Y" are precursors of moiety Y. See Scheme 2 below.
  • desired substitutions at R a can be obtained by selecting, for example, the appropriate compound (Ha) intermediate.
  • moiety X in compound (VTI) is a nitrogen-containing heterocycloalkyl (e.g., piperidine).
  • the nitrogen ring atom can be protected by a nitrogen protecting group (e.g., Cbz, Boc, or FMOC) before coupling to compound (IV) or (IVa) and deprotected afterwards (see first step of Scheme 3) to yield compound (Villa).
  • This compound can further react with various compounds (IX) to produce a compound of formula (I). See second steps of Scheme 3 below.
  • compound (VIII) or compound (Villa) can be a compound of formula (I) as well.
  • TGF]S family signaling pathways can result in excess deposition of extracellular matrix and increased inflammatory responses, which can then lead to fibrosis in tissues and organs (e.g., lung, kidney, and liver) and ultimately result in organ failure.
  • tissues and organs e.g., lung, kidney, and liver
  • fibrosis in tissues and organs (e.g., lung, kidney, and liver) and ultimately result in organ failure.
  • TGFjS and/or activin mR ⁇ A and the level of TGFjS and/or activin are increased in patients suffering from various fibrotic disorders, e.g., fibrotic kidney diseases, alcohol- induced and autoimmune hepatic fibrosis, myelofibrosis, bleomycin-induced pulmonary fibrosis, and idiopathic pulmonary fibrosis. Elevated TGF ⁇ and/or activin is has also been demonstrated in cachexia, demyelination of neurons in multiple sclerosis, Alzheimer's disease, cerebral angiopathy and hypertension.
  • fibrotic disorders e.g., fibrotic kidney diseases, alcohol- induced and autoimmune hepatic fibrosis, myelofibrosis, bleomycin-induced pulmonary fibrosis, and idiopathic pulmonary fibrosis. Elevated TGF ⁇ and/or activin is has also been demonstrated in cachexia, demyelination of neurons in multiple sclerosis, Alzheimer's
  • Compounds of formula (I), which are antagonists of the TGFjS family type I receptors AIk 5 and/or AIk 4, and inhibit TGFjS and/or activin signaling pathway, are therefore useful for treating and/or preventing fibrotic disorders or diseases mediated by an increased level of TGFjS and/or activin activity.
  • a compound inhibits the TGFjS family signaling pathway when it binds (e.g., with an IC 50 value of less than 10 ⁇ M; such as, less than 1 /xM; and for example, less than 5 nM) to a receptor of the pathway (e.g., AIk 5 and/or AIk 4), thereby competing with the endogenous ligand(s) or substrate(s) for binding site(s) on the receptor and reducing the ability of the receptor to transduce an intracellular signal in response to the endogenous ligand or substrate binding.
  • a receptor of the pathway e.g., AIk 5 and/or AIk 4
  • the aforementioned disorders or diseases include any condition (a) marked by the presence of an abnormally high level of TGFjS and/or activin; and/or (b) an excess accumulation of extracellular matrix; and/or (c) an increased number and synthetic activity of myofibroblasts.
  • fibrotic conditions such as scleroderma, glomerulonephritis, diabetic nephropathy, lupus nephritis, hypertension-induced nephropathy, ocular or corneal scarring, alimentary track or gastrointestinal fibrosis, renal fibrosis, hepatic or biliary fibrosis, acute lung injury, pulmonary fibrosis (such as idiopathic pulmonary fibrosis and radiation-induced pulmonary fibrosis), post- infarction cardiac fibrosis, fibrosclerosis, fibrotic cancers, fibroids, fibroma, fibroadenomas, and fibrosarcomas.
  • fibrotic conditions such as scleroderma, glomerulonephritis, diabetic nephropathy, lupus nephritis, hypertension-induced nephropathy, ocular or corneal scarring, alimentary track or gastrointestinal fibrosis, renal fibrosis,
  • fibrotic conditions for which preventive treatment with compounds of formula (I) can have therapeutic utility include radiation-induced fibrosis, chemotherapy- induced fibrosis, and surgically-induced scarring including surgical adhesions, laminectomy, and coronary restenosis.
  • TGF/3 activity is also found to manifest in patients with progressive cancers.
  • the tumor cells, stromal cells, and/or other cells within a tumor generally overexpress TGF /3. This leads to stimulation of angiogenesis and cell motility, suppression of the immune system, and/or increased interaction of tumor cells with the extracellular matrix.
  • the tumors grow more readily, become more invasive and metastasize to distant organs. See, e.g., Maehara, Y.
  • compounds of formula (I), which are antagonists of the TGF/3 type I receptor and inhibit TGF/5 signaling pathways, are also useful for treating and/or preventing various cancers which overexpress TGF/3 or benefit from TGF/3's above-mentioned pro-tumor activities.
  • Such cancers include carcinomas of the lung, breast, liver, biliary tract, gastrointestinal tract, head and neck, pancreas, prostate, cervix as well as multiple myeloma, melanoma, glioma, and glioblastomas.
  • TGF/3 and/or activin e.g., fibrosis or cancers
  • small molecule treatments are favored for long-term treatment.
  • the levels of TGF/3 and/or activin in serum and of TGF/3 and/or activin mRNA in tissue can be measured and used as diagnostic or prognostic markers for disorders or diseases mediated by overexpression of TGF/3 and/or activin, and polymorphisms in the gene for TGF/3 that determine the production of TGF/3 and/or activin can also be used in predicting susceptibility to disorders or diseases. See, e.g., Blobe, G.C. et al., N. Engl. J. Med. 342(18): 1350-1358 (2000); Matsuse, T. et al, Am. J. Respir. Cell MoI. Biol. 13: 17-24 (1995); Inoue, S.
  • an effective amount is the amount required to confer a therapeutic effect on the treated patient.
  • an effective amount can range, for example, from about 1 mg/kg to about 150 mg/kg (e.g., from about 1 mg/kg to about 100 mg/kg).
  • Effective doses will also vary, as recognized by those skilled in the art, dependant on route of administration, excipient usage, and the possibility of co-usage with other therapeutic treatments including use of other therapeutic agents and/or radiation therapy.
  • Compounds of formula (I) can be administered in any manner suitable for the administration of pharmaceutical compounds, including, but not limited to, pills, tablets, capsules, aerosols, suppositories, liquid formulations for ingestion or injection or for use as eye or ear drops, dietary supplements, and topical preparations.
  • the pharmaceutically acceptable compositions include aqueous solutions of the active agent, in an isotonic saline, 5% glucose or other well-known pharmaceutically acceptable excipient.
  • Solubilizing agents such as cyclodextrins, or other solubilizing agents well-known to those familiar with the art, can be utilized as pharmaceutical excipients for delivery of the therapeutic compounds.
  • the compositions can be administered orally, intranasally, transdermally, intradermally, vaginally, intraaurally, intraocularly, buccally, rectally, transmucosally, or via inhalation, implantation (e.g., surgically), or intravenous administration.
  • the compositions can be administered to an animal (e.g., a mammal such as a human, non-human primate, horse, dog, cow, pig, sheep, goat, cat, mouse, rat, guinea pig, rabbit, hamster, gerbil, or ferret, or a bird, or a reptile, such as a lizard).
  • an animal e.g., a mammal such as a human, non-human primate, horse, dog, cow, pig, sheep, goat, cat, mouse, rat, guinea pig, rabbit, hamster, gerbil, or ferret, or a bird, or a reptile, such as a
  • compounds of formula (I) can be administered in conjunction with one or more other agents that inhibit the TGF/3 signaling pathway or treat the corresponding pathological disorders (e.g., fibrosis or progressive cancers) by way of a different mechanism of action.
  • agents include angiotensin converting enzyme inhibitors, nonsteroid and steroid anti-inflammatory agents, immunotherapeutics, chemotherapeutics, as well as agents that antagonize ligand binding or activation of the TGF/3 receptors, e.g., anti-TGF/3, anti-TGF/3 receptor antibodies, or antagonists of the TGF/3 type II receptors.
  • Compounds of formula (I) can also be administered in conjunction with other treatments, e.g., radiation.
  • the invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.
  • Triethylphosphite (0.343 uL, 2.0 mmol) was added to a solution of 4-[l-hydroxy-4-(2- methyl-pyrimidin-4-yl)-5-[l,2,4]triazolo[l,5-a]pyridin-6-yl-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methyl ester (0.40 g, 0.87 mmol; see Example 1 above) in DMF (10 mL). The mixture was heated at 110 0 C for 18 hours. The solvent was removed. The residue was portioned between ethyl acetate and brine.
  • Lithium hydroxide monohydrate (0.046 g, 1.12 mmol) was added to a solution of 4-[4- (2-methyl-pyrimidin-4-yl)-5-[l,2,4]triazolo[l,5-a]pyridin-6-yl-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methyl ester (0.25 g, 0.56 mmol) in a mixture of THF/MeOH/H 2 O (2/1/1, 4 mL). The mixture was stirred for 3 hours, and the solvent was removed. The residue was diluted with water (30 mL). Citric acid was added to the solution to make the pH lower than 7.
  • HATU (0.265 g, 0.70 mmol) was added to a solution of 4-[4-(2-methyl-pyrimidin-4-yl)- 5-[l ,2,4]triazolo[l ,5-a]pyridin-6-yl-lH-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid (0.150 g, 0.35 mmol) and potassium carbonate (0.1242 g, 1.75 mmol) in DMF (5 mL). The mixture was stirred for 10 minutes. NH 3 was bubbled into the reaction mixture for 10 minutes. The mixture was stirre for an additional 2 hours. The mixture was filtered, and DMF was removed under reduced pressure.
  • 1,2-dione 2-oxime (0.6 g, 2.1 mmol) and ammonium acetate (3.1 g, 40 mmol) in acetic acid (30 mL). The mixture was reflux for 2 hours. Solvent was removed under reduced pressure.
  • Trimethylphosphite (1.0 mL, 9.7 mmol) was added to a solution of 4-[l-hydroxy-4-(6- methyl-pyridin-2-yl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methyl ester (0.9 g, 1.93 mmol; see Example 6 above) in
  • Lithium hydroxide monohydrate (0.10 g, 2.44 mmol) was added to 4-[5-(2- Cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methyl ester (0.28 g, 0.61 mmol) in a mixture of THFMeOHTH 2 O (2/1/1, 5 mL). The mixture was stirred for 3 h. Solvent was removed. Residue was diluted with water (30 mL). Citric acid was added to the solution to make the pH lower than 7.
  • HATU (0.17 g, 0.45 mmol) was added to a solution of 4-[5-(2-Cyclopropylamino- pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid (0.10 g, 0.225 mmol; see Example 10 above) and potassium carbonate (0.155 g, 1.13 mmol) in anhydrous DMF (5 mL). The mixture was stirred for 30 minutes. Ammonia was bubbled through the mixture for 10 minutes. The mixture was continued to stir for 2 hours. The mixture was then filtered and concentrated.
  • TGF/3 inhibitory activity of compounds of formula (I) can be assessed by methods described in the following examples.
  • the serine-threonine kinase activity of TGFjS type I receptor was measured as the autophosphorylation activity of the cytoplasmic domain of the receptor containing an N-terminal poly histidine, TEV cleavage site-tag, e.g., His-TGF/3RI.
  • the His-tagged receptor cytoplasmic kinase domains were purified from infected insect cell cultures using the Gibco-BRL FastBac
  • TopCount Packard. Total binding (no inhibition) was defined as counts measured in the presence of DMSO solution containing no test compound and non-specific binding was defined as counts measured in the presence of EDTA or no-kinase control.
  • Compounds of formula (I) typically exhibited IC 50 values of less than 10 ⁇ M; some exhibited IC 50 values of less than 1 ⁇ M; and some even exhibited IC50 values of less than 50 nM.
  • His-TGFjS Type I receptor in the same assay buffer Hepes, NaCl 2 , MgCl 2 , MnCl 2 , DTT, and 30% Brij ® added fresh
  • Biological activity of the compounds of formula (I) was determined by measuring their ability to inhibit TGF/3-induced PAI-Luciferase reporter activity in HepG2 cells.
  • HepG2 cells were stably transfected with the PAI-luciferase reporter grown in DMEM medium containing 10% FBS, penicillin (100 U/mL), streptomycin (100 ⁇ g/mL), L-glutamine (2 mM), sodium pyruvate (1 mM), and non-essential amino acids (Ix).
  • the transfected cells were then plated at a concentration of 2.5 x 10 4 cells/well in 96 well plates and starved for 3-6 hours in media with 0.5% FBS at 37 0 C in a 5% CO 2 incubator.
  • the cells were then stimulated with 2.5 ng/mL TGF/3 ligand in the starvation media containing 1% DMSO either in the presence or absence of a test compound of formula (I) and incubated as described above for 24 hours.
  • the media was washed out the following day and the luciferase reporter activity was detected using the LucLite Luciferase Reporter Gene Assay kit (Packard, cat. no. 6016911) as recommended.
  • the plates were read on a Wallac Microbeta plate reader, the reading of which was used to determine the IC 50 values of " compounds of formula (I) for inhibiting TGF/3-induced
  • test compounds of formula (I) The cellular inhibition of activin signaling activity by the test compounds of formula (I) is determined in a similar manner as described above in Example 37 except that 100 ng/mL of activin is added to serum starved cells in place of the 2.5 ng/mL TGF/3.
  • Fibroblasts are derived from the skin of adult transgenic mice expressing Green
  • GFP Fluorescent Protein
  • Cells are thawed, plated in complete DMEM (contains non-essential amino acids, ImM sodium pyruvate and 2mM L-glutamine) with 10 % fetal calf serum, and then incubated for overnight at 37 0 C, 5% CO 2 . The cells are trypsinized in the following day and transferred into complete DMEM (contains non-essential amino acids, ImM sodium pyruvate and 2mM L-glutamine) with 10 % fetal calf serum, and then incubated for overnight at 37 0 C, 5% CO 2 . The cells are trypsinized in the following day and transferred into complete DMEM (contains non-essential amino acids, ImM sodium pyruvate and 2mM L-glutamine) with 10 % fetal calf serum, and then incubated for overnight at 37 0 C, 5% CO 2 . The cells are trypsinized in the following day and transferred into complete DMEM (

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compounds of formula (I) possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. The invention features a compound of the general formula (I) and uses thereof.

Description

PYRIMIDINYLIMIDAZOLES AS TGF-BETA INHIBITORS
[0001] This application claims priority to U.S. Serial No. 60/606,045, which was filed on August 31, 2004. The entire contents of the aforementioned application are incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0002] TGF/3 (Transforming Growth Factor /3) is a member of a large family of dimeric polypeptide growth factors that includes, for example, activins, inhibins, bone morphogenetic proteins (BMPs), growth and differentiation factors (GDFs) and mullerian inhibiting substance (MIS). TGF/3 exists in three isoforms (TGF/31, TGF/32, and TGF/33) and is present in most cells, along with its receptors. Each isoform is expressed in both a tissue-specific and developmentally regulated fashion. Each TGF/3 isoform is synthesized as a precursor protein that is cleaved intracellularly into a C-terminal region (latency associated peptide (LAP)) and an N-terminal region known as mature or active TGF/3. LAP is typically non-covalently associated with mature TGF/3 prior to secretion from the cell. The LAP-TGF/3 complex cannot bind to the TGF 'β receptors and is not biologically active. TGF β is generally released (and activated) from the complex by a variety of mechanisms including, for example, interaction with thrombospondin-1 or plasmin.
[0003] Following activation, TGF/3 binds at high affinity to the type II receptor (TGF/3RII), a constitutively active serine/threonine kinase. The ligand-bound type II receptor phosphorylates the TGF/3 type I receptor (AIk 5) in a glycine/serine rich domain, which allows the type I receptor to recruit and phosphorylate downstream signaling molecules, Smad2 or Smad3. See, e.g., Huse, M. et al., MoI. Cell. 8: 671-682 (2001). Phosphorylated Smad2 or Smad3 can then complex with Smad4, and the entire hetero-Smad complex translocates to the nucleus and regulates transcription of various TGF/3-responsive genes. See, e.g., Massague, J. Ann. Rev .Biochem. Med. 67: 773 (1998).
[0004] Activins are also members of the TGF/3 superfamily, which are distinct from TGF/3 in that they are homo- or heterodimers of activin /3a or /3b. Activins signal in a manner similar to TGF/3 , that is, by binding to a constitutive serine-threonine receptor kinase, activin type II receptor (ActRIIB), and activating a type I serine-threonine receptor, AIk 4, to phosphorylate Smad2 or Smad3. The consequent formation of a hetero-Smad complex with Smad4 also results in the activin-induced regulation of gene transcription.
[0005] Indeed, TGF/3 and related factors such as activin regulate a large array of cellular processes, e.g., cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, inflammatory cell recruitment, immunosuppression, wound healing, and extracellular matrix production. See, e.g., Massague, J. Ann. Rev .Cell. Biol. 6: 594-641 (1990); Roberts, A. B. and Sporn M. B. Peptide Growth Factors and Their Receptors, 95: 419-472 Berlin: Springer- Verlag (1990); Roberts, A. B. and Sporn M. B. Growth Factors 8:1-9 (1993); and Alexandrow, M. G., Moses, H. L. Cancer Res. 55: 1452-1457 (1995). Hyperactivity of TGFjS signaling pathway underlies many human disorders (e.g., excess deposition of extracellular matrix, an abnormally high level of inflammatory responses, fibrotic disorders, and progressive cancers). Similarly, activin signaling and overexpression of activin is linked to pathological disorders that involve extracellular matrix accumulation and fibrosis (see, e.g., Matsuse, T. et al., Am. J. Respir. Cell MoI. Biol. 13: 17-24 (1995); Inoue, S. et al., Biochem. Biophys. Res. Comm. 205: 441-448 (1994); Matsuse, T. et εΛ, Am. J. Pathol. 148: 707- 713 (1996); De Bleser et al., Hepatology 26: 905-912 (1997); Pawlowski, J.E., et al., J. Clin. Invest. 100: 639-648 (1997); Sugiyama, M. et al., Gastroenterology 114: 550-558 (1998); Munz, B. et al., EMBOJ. 18: 5205-5215 (1999)), inflammatory responses (see, e.g., Rosendahl, A. et al., Am. J. Repir. Cell MoI. Biol. 25: 60-68 (2001)), cachexia or wasting (see Matzuk, M. M. et al., Proc. Nat. Acad. ScL USA 91: 8817-8821 (1994); Coerver, K.A. et al, MoI. Endocrinol. 10: 534-543 (1996); Cipriano, S.C. et al. Endocrinology 141: 2319-27 (2000)), diseases of or pathological responses in the central nervous system (see Logan, A. et al. Eur. J. Neurosci. 11 : 2367-2374 (1999); Logan, A. et al. Exp. Neurol. 159: 504-510 (1999); Masliah, E. et al., Neurochem. Int. 39: 393-400 (2001); De Groot, C. J. A. et al, J. Neuropathol. Exp. Neurol. 58: 174-187 (1999), John, G. R. et al, Nat Med. 8: 1115-21 (2002)) and hypertension (see Dahly, A. J. et al., Am. J. Physiol. Regul. Integr. Comp. Physiol. 283: R757-67 (2002)). Studies have shown that TGFβ and activin can act synergistically to induce extracellular matrix production (see, e.g., Sugiyama, M. et al., Gastroenterology 114: 550-558, (1998)). It is therefore desirable to develop modulators (e.g., antagonists) to members of the TGFjS family to prevent and/or treat disorders involving this signaling pathway.
SUMMARY OF THE INVENTION
[0006] The invention is based on the discovery that compounds of formula (I) are unexpectedly potent antagonists of the TGF β family type I receptors, Alk5 and/or AIk 4. Thus, compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGFjS family signaling activity is desirable. [0007] In one aspect, a compound of the following formula: where R1 can be heteroaryl.
[0008] Each Ra, independently, can be alkyl, alkenyl, alkynyl, alkoxy, acyl, halo, hydroxy, amino, nitro, oxo, thioxo, cyano, guanadino, amidino, carboxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkoxycarbonyl, alkylcarbonyloxy, urea, thiourea, sulfamoyl, sulfamide, carbamoyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfanyl, cycloalkylcarbonyl, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylsulfanyl, heterocycloalkylcarbonyl, aryl, aryloxy, arylsulfanyl, aroyl, heteroaryl, heteroaryloxy, heteroarylsulfanyl, or heteroaroyl. [0009] X can be cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or a bond. [0010] Y can be a bond, -C(O)-, -C(O)-O-, -O-C(O)-, -S(O)P-O-, -O-S(O)P-, -C(O)-N(Rb)-, -N(Rb)-C(O)-, -O-C(O)-N(Rb)-, -N(Rb)-C(O)-O-, -C(O)-N(Rb)-O-, -O-N(Rb)-C(O)-, -O-S(O)p-N(Rb)-, -N(Rb)- S(O)p-O-, -S(O)p-N(Rb)-O-, -O-N(Rb)-S(O)p-, -N(Rb)-C(O)-N(Rc)-, -N(Rb)-S(O)p-N(Rc)-, -C(O)-N(Rb)-S(O)p-, -S(O)p-N(Rb)-C(O>, -C(O)-N(Rb)-S(O)p-N(Rc)-, -C(O)-O-S(O)p-N(Rb)-, -N(Rb)-S(O)p-N(Rc)-C(O)-, -N(Rb)-S(O)p-O-C(O)-, -S(O)p-N(Rb)-, -N(Rb)-S(O)p-, -N(Rb)-, -S(O)p-, -O-, -S-, or -(C(Rb)(Rc))q-. Each of Rb and Rc , independently, can be hydrogen, hydroxy, alkyl, alkoxy, amino, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroaralkyl. p can be 1 or 2, and q can be 1-4.
[0011] R2 can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, aralkyl, arylalkenyl, heterocycloalkyl, (heterocycloalkyl)alkyl, heterocycloalkenyl, (heterocycloalkenyl)alkyl, heteroaryl, heteroaralkyl, or (heteroaryl)alkenyl. [0012] Each of A1 and A2, independently, can be N or NRb. It is to be understood that when A1 is NRb, A2 is N, and vice versa. The variable, m, can be 0, 1, 2, or 3. In other words, the pyrimidinyl ring cari be unsubstituted or substituted with 1-3 Ra groups. Note that when m >2, two adjacent Ra groups can join together to form a 4- to 8-membered optionally substituted cyclic moiety. That is, the pyrimidinyl ring can fuse with a cyclic moiety to form a moiety, that can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, heteroaryl, aryloxy, heteroaryloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylthio, sulfoxy, sulfamoyl, oxo, or carbamoyl. [0013] Note also that if X is a bond, then Y is a bond; R2 is hydrogen or alkyl; m is 1, 2, or 3; and at least one Ra is substituted at the 2-pyrimidinyl position (i.e., the position of the pyrimidinyl ring that is between the two nitrogen ring atoms).
[0014] In an embodiment, X can be aryl or heteroaryl. For example, X can be an optionally substituted phenyl (e.g., alkyl or cyano). Y can be a bond, -N(Rb)-C(O)-, -N(Rb)-S(O)2-, -C(O)-, -C(O)-O-, -0-C(O)-, -C(O)-N(Rb)-, -S(OV, -O", -S(O)2-N(Rb)-, - N(Rb)-, -N(Rb)-C(O)-O-, -N(Rb)-C(O)-N(Rc)-, -C(O)-N(Rb)-S(O)p-N(Rc)-, or -C(O)-O-S(O)p-N(Rb)-. R2 can be hydrogen, Ci-6 alkyl, aryl, heteroaryl, aryl-Ci^ alkyl, or heteroaryl-C^ alkyl. [0015] In an embodiment, X can be a 4- to 8-membered monocyclic cycloalkyl or heterocycloalkyl, or X can be a 4- to 8-membered bicyclic cycloalkyl or heterocycloalkyl. For example, X can be piperidinyl, piperazinyl, pyrrolidinyl, tetrahydrofuran, cyclohexyl, cyclopentyl, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.1]octane, 2-oxa-bicyclo[2.2.2]octane, 2-aza-bicyclo[2.2.2]octane, 3-aza-bicyclo[3.2.1]octane, or 1 -aza-bicyclo[2.2.2]octane.
[0016] In an embodiment, X can be piperidinyl, piperazinyl, or pyrrolidinyl. The piperdinyl, piperazinyl, or pyrrolidinyl can be bonded to Y via its nitrogen ring atom. Y can be a bond, -C(O)O-, -C(O)-N(Rb)-, -S(O)2-, or -S(O)2-N(R*3)-, wherein Rb is hydrogen or CM alkyl. Alternatively, X can be cyclohexyl, cyclopentyl, or bicyclo[2.2.2]octane, and Y can be -N(Rb)-C(O)-, -N(Rb)-S(O)2-, -C(O)-, -C(O)-O-, -0-C(O)-, -C(O)-N(Rb)-, -S(OV, -O-, -S(O)2-N(Rb)-, - N(Rb)-, -N(Rb)-C(0)-0-, -C(O)-N(Rb)-O-, or -N(Rb)-C(O)-N(Rc)-. [0017] In an embodiment, Y can be -N(Rb)-C(0)-, -N(Rb)-S(O)2-, -C(O)-, -C(O)-O-, -0-C(O)-, -C(O)-N(Rb)-, -S(OV, -O-, -S(O)2-N(Rb)-, - N(Rb)-, -N(Rb)-C(O)-O-, -C(O)-N(Rb)-O-, -N(Rb)-C(0)-N(Rc)-, -C(O)-N(Rb)-S(O)p-N(Rc)-, or -C(O)-O-S(O)p-N(Rb)-. [0018] In an embodiment, X and Y are each a bond; R2 can be hydrogen or C1-6 alkyl (e.g., Ci-4 alkyl such as methyl or t-butyl); m can be 1 or 2 (e.g., m can be 1); at least one Ra is substituted at the 2-pyrimidinyl position and this Ra can be Ci-4 alkyl, C3-6 cycloalkyl, or amino (e.g, -CH3, - CF3, cyclopropyl, -NH2, -NH-C1-4 alkyl, or -NH-cycloalkyl such as -NH-cyclopropyl). [0019] In an embodiment, R2 can be hydrogen, C1-6 alkyl, aryl, heteroaryl, aryl-Ci^ alkyl, or heteroaryl-Ci-4 alkyl. In an embodiment, R2 can be hydrogen, Ci-4 alkyl, phenyl, pyridyl, imidazolyl, furanyl, thienyl, triazolyl, tetrazolyl, benzyl, phenylethyl, benzimidazolyl, benzothiazolyl, naphthylmethyl, naphthylethyl, or -Ci-2 alkyl-pyridyl; each of which, independently, is optionally substituted with one or more substituents selected from the group consisting of fluoro, chloro, trifluoromethyl, methyl, ethyl, aminocarbonyl, alkylcarbonylamino, sulfamoyl, alkoxycarbonyl, and alkylcarbonyloxy.
[0020] In another embodiment, R" can be hydrogen, methyl, ethyl, n-butyl, t-butyl, benzyl or pyridylmethyl. For example, R2 can be hydrogen, hydroxymethyl, or trifluoromethyl.
[0021] In an embodiment, R1 can be benzo[l,3]dioxolyl, benzo[έ]thiophenyl, benzo-oxadiazolyl, benzothiadiazolyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl,
2-oxo-benzooxazolyl, pyridyl, pyrimidinyl, 2,3-dihydro-benzo[l,4]dioxyl,
2,3-dihydro-benzofuryl, 2,3-dihydro-benzo[έ]thiophenyl, 3,4-dihydro-benzo[l ,4]oxazinyl,
3 -oxo-benzo[ 1 ,4] oxazinyl, 1 , 1 -dioxo-2,3 -dihydro- benzo [έ]thiophenyl,
[l,2,4]triazolo[l,5-a]pyridyl, [l,2,4]triazolo[4,3-a]pyridyl, quinolinyl, quinoxalinyl, quinazolinyl, isoquinolinyl, or cinnolinyl.
[0022] In an embodiment, m can be 0-2.
[0023] In an embodiment, Ra can be substituted at the 2-pyrimidinyl position.
[0024] In another embodiment, Ra can be C1-4 alkyl, C1-4 alkoxy, Ci-4 alkylthio, halo, amino, aminocarbonyl, or alkoxycarbonyl.
[0025] In an embodiment, A1 can be N and A2 is NRb, or A1 is NRb and A2 is N; wherein Rb is hydrogen or Ci-4 alkyl.
[0026] In an embodiment, m can be 0-2; R1 can be heteroaryl; R2 can be hydrogen, C1^ alkyl, aryl, heteroaryl, -Ci-4 alkyl-aryl, Or -Ci-4 alkyl-heteroaryl; X can be a 4- to 8-membered monocyclic or bicyclic cycloalkyl or heterocycloalkyl; and Y can be -N(Rb)-C(O)-,
-N(Rb)-S(O)2-, -C(O)-, -C(O)-O-, -0-C(O)-, -C(O)-N(Rb)-, -S(O)P-, -O-, -S(O)2-N(Rb)-,
-N(Rb)-, -N(Rb)-C(O)-O-, -N(Rb)-C(O)-N(Rc)-, -C(O)-N(Rb)-S(O)p-N(Rc)-, or
-C(O)-O-S(O)p-N(Rb)-.
[0027] In an embodiment, m can be 0-2; R1 can be heteroaryl; R2 can be hydrogen, Ci-6 alkyl, aryl, heteroaryl, -Ci-4 alkyl-aryl, or -Ci-4 alkyl-heteroaryl; X can be piperidinyl, piperazinyl, pyrrolidinyl, tetrahydrofuran, cyclohexyl, cyclopentyl, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.1]octane, 2-oxa-bicyclo[2.2.2]octane,
2-aza-bicyclo[2.2.2]octane, 3-aza-bicyclo[3.2.1]octane, or l-aza-bicyclo[2.2.2]octane; and Y can be -N(Rb)-C(O)-, -N(Rb)-S(O)2-, -C(O)-, -C(O)-O-, -0-C(O)-, -C(O)-N(Rb)-, -S(O)P-, -O-,
-S(O)2-N(Rb)-, - N(Rb)-, -N(Rb)-C(O)-O-, -N(Rb)-C(O)-N(Rc)-, -C(O)-N(Rb)-S(O)p-N(Rc)-, or
-C(O)-O-S(O)p-N(Rb)-.
[0028] In an embodiment, m can be 0-2; R1 can be heteroaryl; R2 can be hydrogen, Ci-6 alkyl, aryl, heteroaryl, -Ci-4 alkyl-aryl, Or -Ci-4 alkyl-heteroaryl; and -X-Y- can be
[0029] In an embodiment, A1 can be N and A2 can be NH. Alternatively, A1 can be NH and A2 can be N. R2 can be hydrogen, Ci-4 alkyl, benzyl, or pyridylmethyl; m can be 1 and Ra can be substituted at the 2-pyrimidinyl position.
[0030] In an embodiment, m can be 0-2; R1 can be heteroaryl; R2 can be hydrogen, Ci-6 alkyl, aryl, heteroaryl, aryl-Ci^ alkyl, or heteroaryl-CM alkyl; X can be cyclohexyl, cyclopentyl, or bicyclo[2.2.2]octane; and Y can be -N(Rb)-C(0)-, -N(Rb)-S(O)2-, -C(O)-, -C(O)-O-, -0-C(O)-,
-C(O)-N(Rb)-, -S(OV-, -O-, -S(O)2-N(Rb)-, - N(Rb)-, -N(Rb)-C(O)-O-, -N(Rb)-C(0)-N(Rc)-,
-C(O)-N(Rb)-S(O)p-N(Rc)-, or -C(O)-O-S(O)p-N(Rb)-. Each of Rb and Rc, independently, can be hydrogen or Ci-4 alkyl. A1 can be N and A2 can be NH, or alternatively, A1 can be NH and A2 can be N. R2 can be hydrogen, Ci-4 alkyl, benzyl, or pyridylmethyl; m can be 1 and Ra can be substituted at the 2-pyrimindyl position.
[0031] In an embodiment, X and Y can each be a bond; R2 can be hydrogen or Ci-4 alkyl; m can be 1; Ra can be -CH3, -CF3, cyclopropyl, -NH2, -NH-Ci-4 alkyl, or -NH-cycloalkyl; and R1 can be benzo[l,3]dioxolyl, benzo[6]thiophenyl, benzooxadiazolyl, benzothiadiazolyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, 2-oxo-benzooxazolyl, pyridyl, pyrimidinyl,
2,3-dihydro-benzo[l ,4]dioxyl, 2,3-dihydro-benzofuryl, 2,3-dihydro-benzo[Z?]thiophenyl,
3,4-dihydro-benzo[l,4]oxazinyl, 3-oxo-benzo[l,4]oxazinyl, l,l-dioxo-2,3-dihydro- benzo[δ]thiophenyl, [l,2,4]triazolo[l,5-a]pyridyl, [l,2,4]triazolo[4,3-a]pyridyl, quinolinyl, quinoxalinyl, quinazolinyl, isoquinolinyl, or cinnolinyl.
[0032] The compound of formula (I) can be:
[0033] 4-[4-benzo[l,3]dioxol-5-yl-5-(2-methylsulfanyl-pyrimidin-4-yl)-lH-imidazol-2-yl]- benzamide;
[0034] 4-[4-benzo[l,3]dioxol-5-yl-5-(2-methylsulfanyl-pyrimidin-4-yl)-lH-imidazol-2-yl]- benzonitrile;
[0035] 4-[5-(2-methanesulfonyl-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methyl ester;
[0036] 4-[5-(2-methoxy-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methyl ester;
[0037] 4-[5-(2-hydroxy-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methyl ester;
[0038] 4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methyl ester;
[0039] 4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid;
[0040] 4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid amide;
[0041] 4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid hydroxyamide;
[0042] 4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methoxy-amide;
[0043] 4-[5-(2-amino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid;
[0044] {4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2- yl]-bicyclo[2.2.2]oct-l-yl}-carbamic acid benzyl ester;
[0045] N- {4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)- 1 H-imidazol-
2-yl]-bicyclo[2.2.2]oct-l-yl}-acetamide;
[0046] N-{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-
2-yl]-bicyclo[2.2.2]oct-l-yl}-methanesulfonamide;
[0047] N- {4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)- 1 H-imidazol-
2-yl]-bicyclo[2.2.2]oct-l-yl}-2,2,2-trifluoro-acetamide;
[0048] 4-[5-quinoxalin-6-yl-4-(2-trifluoromethyl-pyrimidin-4-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octan-l-ol;
[0049] 4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-lH-imidazol-2-yl]- bicyclo[2.2.2]octan-l-ol;
[0050] 6-[2-tert-butyl-5-(2-cyclopropyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
(15686)
[0051] 6-[5-(2-byclopropyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
[0052] {4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-lH-imidazol-2-yl]- bicyclo[2.2.2]oct-l-yl}-methanol; [0053] 6-[5-(2-trifluoromethyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
[0054] 6-[2-tert-butyl-5-(2-trifluoromethyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
[0055] 4-[5-quinoxalin-6-yl-4-(2-trifluoromethyl-pyrimidin-4-yl)-lH-imidazol-2-yl]-piperidine-
1-carboxylic acid benzyl ester;
[0056] 4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-lH-imidazol-2-yl]-piperidine-l- carboxylic acid benzyl ester;
[0057] 6-[5-(2-cyclopropyl-pyrimidin-4-yl)-2-(l-methanesulfonyl-piperidin-4-yl)-3H-imidazol-
4-yl] -quinoxaline;
[0058] 4-[5-(2-methyl-pyrimidin-4-yl)-4-[l,2,4]triazolo[4,3-a]pyridin-6-yl-lH-imidazol-2-yl]- bicyclo[2.2.2]octan-l -ol;
[0059] 4-[4-(2-methyl-pyrimidin-4-yl)-5-[l,2,4]triazolo[l,5-a]pyridin-6-yl-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid amide;
[0060] 4-[4-(2-methyl-pyrimidin-4-yl)-5-[l,2,4]triazolo[l,5-a]pyridin-6-yl-lH-imidazol-2-yl]- bicyclo [2.2.2] octane- 1 -carboxylic acid;
[0061] 4-[4-(2-methyl-pyrimidin-4-yl)-5-[l,2,4]triazolo[l,5-a]pyridin-6-yl-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methyl ester;
[0062] 4-[4-(2-methyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-lH-imidazol-2-yl]-cyclohexanol; or
[0063]4-[4-(2-methyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-lH-imidazol-2-yl]-bicyclo[2.2.2]octan- l-ol.
[0064] In another aspect, a pharmaceutical composition includes a compound of formula (I) and a pharmaceutically acceptable carrier.
[0065] In another aspect, a method of inhibiting the TGF/3 signaling pathway in a subject includes administering to said subject an effective amount of a compound of formula (I).
[0066] In another aspect, a method of inhibiting the TGF/3 type I receptor in a cell, includes contacting said cell with an effective amount of a compound of formula (I).
[0067] In another aspect, a method of reducing the accumulation of excess extracellular matrix induced by TGF/3 in a subject includes administering to said subject an effective amount of a compound of formula (I).
[0068] In another aspect, a method of treating or preventing fibrotic condition in a subject includes administering to said subject an effective amount of a compound of formula (I). The fibrotic condition can be, for example, scleroderma, lupus nephritis, connective tissue disease, wound healing, surgical scarring, spinal cord injury, CNS scarring, acute lung injury, pulmonary fibrosis (such as idiopathic pulmonary fibrosis), chronic obstructive pulmonary disease, adult respiratory distress syndrome, drug-induced lung injury, glomerulonephritis, diabetic nephropathy, hypertension-induced nephropathy, alimentary track or gastrointestinal fibrosis, renal fibrosis, hepatic or biliary fibrosis (such as liver cirrhosis, primary biliary cirrhosis, fatty liver disease, primary sclerosing cholangitis), restenosis, cardiac fibrosis, opthalmic scarring, fibrosclerosis, fibrotic cancers, fibroids, fibroma, fibroadenomas, fibrosarcomas, transplant arteriopathy, or keloid. The fibrotic condition can be idiopathic in nature, genetically linked, or induced by radiation.
[0069] In another aspect, a method of inhibiting growth or metastasis of tumor cells and/or cancers in a subject includes administering to said subject an effective amount of a compound of formula (I).
[0070] In another aspect, a method of treating a disease or disorder mediated by an overexpression of TGF β includes administering to a subject in need of such treatment an effective amount of a compound of formula (I). The disease or disorder can be, for example, demyelination of neurons in multiple sclerosis, Alzheimer's disease, cerebral angiopathy, squamous cell carcinomas, multiple myeloma, melanoma, glioma, glioblastomas, leukemia, sarcomas, leiomyomas, mesothelioma, or carcinomas of the lung, breast, ovary, cervix, liver, biliary tract, gastrointestinal tract, pancreas, prostate, and head and neck.
[0071] An N-oxide derivative or a pharmaceutically acceptable salt of each of the compounds of formula (I) is also within the scope of this invention. For example, a nitrogen ring atom of the imidazole core ring or a nitrogen-containing heterocyclyl substituent can form an oxide in the presence of a suitable oxidizing agent such as m-chloroperbenzoic acid or H2O2. [0072] A compound of formula (I) that is acidic in nature (e.g., having a carboxyl or phenolic hydroxyl group) can form a pharmaceutically acceptable salt such as a sodium, potassium, calcium, or gold salt. Also within the scope of the invention are salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, and Ν-methylglycamine. A compound of formula (I) can be treated with an acid to form acid addition salts. Examples of such acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, methanesulfonic acid, phosphoric acid,/>-bromophenyl-sulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, oxalic acid, malonic acid, salicylic acid, malic acid, fumaric acid, ascorbic acid, maleic acid, acetic acid, and other mineral and organic acids well known to those skilled in the art. The acid addition salts can be prepared by treating a compound of formula (I) in its free base form with a sufficient amount of an acid (e.g., hydrochloric acid) to produce an acid addition salt (e.g., a hydrochloride salt). The acid addition salt can be converted back to its free base form by treating the salt with a suitable dilute aqueous basic solution (e.g., sodium hydroxide, sodium bicarbonate, potassium carbonate, or ammonia). Compounds of formula (1) can also be, e.g., in a form of achiral compounds, racemic mixtures, optically active compounds, pure diastereomers, or a mixture of diastereomers. [0073] Compounds of formula (I) exhibit surprisingly high affinity to the TGF/3 family type I receptors, AIk 5 and/or AIk 4, e.g., with ICs0 and Kj values of less than 10 μM under conditions as described below in Examples 34 and 36, respectively. Some compounds of formula (I) exhibit IC50 and K; values of less than 1 μM (such as below 50 nM).
[0074] Compounds of formula (I) can also be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and include those that increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism, and/or alter rate of excretion. Examples of these modifications include, but are not limited to, esterifϊcation with polyethylene glycols, derivatization with pivolates or fatty acid substituents, conversion to carbamates, hydroxylation of aromatic rings, and heteroatom-substitution in aromatic rings. [0075] The present invention also features a pharmaceutical composition comprising a compound of formula (I) (or a combination of two or more compounds of formula (I)) and at least one pharmaceutically acceptable carrier. Also included in the present invention is a medicament composition including any of the compounds of formula (I), alone or in a combination, together with a suitable excipient.
[0076] The invention also features a method of inhibiting the TGF/3 family type I receptors, AIk 5 and/or AIk 4 (e.g., with an IC50 value of less than 10 μM; such as, less than 1 μM; and for example, less than 5 nM) in a cell, including the step of contacting the cell with an effective amount of one or more compounds of formula (I). Also within the scope of the invention is a method of inihibiting the TGF/3 and/or activin signaling pathway in a cell or in a subject (e.g., a mammal such as a human), including the step of contacting the cell with or administering to the subject an effective amount of one or more of the compounds of formula (I). [0077] Also within the scope of the present invention is a method of treating a subject or preventing a subject from suffering a condition characterized by or resulted from an elevated level of TGF/3 and/or activin activity. The method includes the step of administering to the subject an effective amount of one or more of a compound of formula (I). The conditions include an accumulation of excess extracellular matrix; a fibrotic condition (which can be induced by drug or radiation), e.g., scleroderma, lupus nephritis, connective tissue disease, wound healing, surgical scarring, spinal cord injury, CNS scarring, acute lung injury, pulmonary fibrosis (such as idiopathic pulmonary fibrosis and radiation-induced pulmonary fibrosis), chronic obstructive pulmonary disease, adult respiratory distress syndrome, acute lung injury, drug-induced lung injury, glomerulonephritis, diabetic nephropathy, hypertension-induced nephropathy, alimentary track or gastrointestinal fibrosis, renal fibrosis, hepatic or biliary fibrosis, liver cirrhosis, primary biliary cirrhosis, cirrhosis due to fatty liver disease (alcoholic and nonalcoholic steatosis), primary sclerosing cholangitis, restenosis, cardiac fibrosis, opthalmic scarring, fibrosclerosis, fibrotic cancers, fibroids, fibroma, fibroadenomas, fibrosarcomas, transplant arteriopathy, and keloid); TGF/3-induced growth or metastasis of tumor/cancer cells; and carcinomas (e.g, squamous cell carcinomas, multiple myeloma, melanoma, glioma, glioblastomas, leukemia, sarcomas, leiomyomas, mesothelioma, and carcinomas of the lung, breast, ovary, cervix, liver, biliary tract, gastrointestinal tract, pancreas, prostate, and head and neck); and other conditions such as cachexia, hypertension, ankylosing spondylitis, demyelination in multiple sclerosis, cerebral angiopathy and Alzheimer's disease. [0078] As used herein, an "alkyl" group refers to a saturated aliphatic hydrocarbon group containing 1-8 (e.g., 1-6 or 1-4) carbon atoms. An alkyl group can be straight or branched. Examples of an alkyl group include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-heptyl, and 2-ethylhexyl. An alkyl group can be optionally substituted with one or more substituents such as alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, amino, nitro, carboxy, cyano, halo, hydroxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, cycloalkyl-alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, heterocycloalkyl-carbonylamino, heterocycloalkyl- alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, urea, thiourea, sulfamoyl, sulfamide, alkoxycarbonyl, or alkylcarbonyloxy.
[0079] As used herein, an "alkenyl" group refers to an aliphatic carbon group that contains 2-8 (e.g., 2-6 or 2-4) carbon atoms and at least one double bond. Like an alkyl group, an alkenyl group can be straight or branched. Examples of an alkenyl group include, but are not limited to, allyl, isoprenyl, 2-butenyl, and 2-hexenyl. An alkenyl group can be optionally substituted with one or more substituents such as alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, amino, nitro, carboxy, cyano, halo, hydroxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, cycloalkyl-alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, heterocycloalkyl-carbonylamino, heterocycloalkyl-alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, urea, thiourea, sulfamoyl, sulfamide, alkoxycarbonyl, or alkylcarbonyloxy. [0080] As used herein, an "alkynyl" group refers to an aliphatic carbon group that contains 2-8 (e.g., 2-6 or 2-4) carbon atoms and has at least one triple bond. An alkynyl group can be straight or branched. Examples of an alkynyl group include, but are not limited to, propargyl and butynyl. An alkynyl group can be optionally substituted with one or more substituents such as alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, amino, nitro, carboxy, cyano, halo, hydroxy, sulfo, mercapto, alkylsulfanyl, alkylsulfmyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, cycloalkyl-alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, heterocycloalkyl- carbonylamino, heterocycloalkyl-alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, urea, thiourea, sulfamoyl, sulfamide, alkoxycarbonyl, or alkylcarbonyloxy.
[0081] As used herein, an "amino" group refers to -NRXRY wherein each of Rx and Rγ is independently hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, aryl, aralkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, heteroaryl, or heteroaralkyl. When the term "amino" is not the terminal group (e.g., alkylcarbonylamino), it is represented by -NRX-. Rx has the same meaning as defined above.
[0082] As used herein, an "aryl" group refers to phenyl, naphthyl, or a benzofused group having 2 to 3 rings. For example, a benzofused group includes phenyl fused with one or two C4-8 carbocyclic moieties, e.g., 1, 2, 3, 4-tetrahydronaphthyl, indanyl, or fluorenyl. An aryl is optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkyl)alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkyl)alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.
[0083] As used herein, an "aralkyl" group refers to an alkyl group (e.g., a C1-4 alkyl group) that is substituted with an aryl group. Both "alkyl" and "aryl" have been defined above. An example of an aralkyl group is benzyl.
[0084] As used herein, a "cycloalkyl" group refers to an aliphatic carbocyclic ring of 3-10 (e.g., 4-8) carbon atoms. Examples of cycloalkyl groups include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, norbornyl, cubyl, octahydro-indenyl, decahydro-naphthyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, and bicyclo[3.2.3]nonyl. A "cycloalkenyl" group, as used herein, refers to a non-aromatic carbocyclic ring of 3-10 (e.g., 4- 8) carbon atoms having one or more double bond. Examples of cycloalkenyl groups include cyclopentenyl, 1,4-cyclohexa-di-enyl, cycloheptenyl, cyclooctenyl, hexahydro-indenyl, octahydro-naphthyl, bicyclo[2.2.2]octenyl, and bicyclo[3.3.1]nonenyl. A cycloalkyl or cycloalkenyl group can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkyl)alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkyl)alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.
[0085] As used herein, a "heterocycloalkyl" group refers to a 3- to 10-membered (e.g., 4- to 8- membered) saturated ring structure, in which one or more of the ring atoms is a heteroatom, e.g., N, O, or S. Examples of a heterocycloalkyl group include piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrofuryl, dioxolanyl, oxazolidinyl, isooxazolidinyl, morpholinyl, octahydro-benzofuryl, octahydro-chromenyl, octahydro-thiochromenyl, octahydro-indolyl, octahydro-pyrindinyl, decahydro-quinolinyl, octahydro-benzo[Z>]thiophenyl, 2-oxa- bicyclo[2.2.2]octyl, l-aza-bicyclo[2.2.2]octyl, 3-aza-bicyclo[3.2.1]octyl, anad 2,6-dioxa- tricyclo[3.3.1.03'7]nonyl. A "heterocycloalkenyl" group, as used herein, refers to a 3- to 10- membered (e.g., 4- to 8-membered) non-aromatic ring structure having one or more double bonds, and wherein one or more of the ring atoms is a heteroatom, e.g., N, O, or S. A heterocycloalkyl or heterocycloalkenyl group can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalky^alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalky^carbonylamino, (heterocycloalkytyalkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.
[0086] A "heteroaryl" group, as used herein, refers to a monocyclic, bicyclic, or tricyclic ring structure having 5 to 15 ring atoms wherein one or more of the ring atoms is a heteroatom, e.g.,
N, O, or S and wherein one ore more rings of the bicyclic or tricyclic ring structure is aromatic.
Some examples of heteroaryl are pyridyl, furyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, indolyl, tetrazolyl, benzofuryl, benzthiazolyl, xanthene, thioxanthene, phenothiazine, dihydroindole, and benzo[l,3]dioxole. A heteroaryl is optionally substituted with one or more substiruents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl,
(heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkyl)alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkyl)alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl. A
"heteroaralkyl" group, as used herein, refers to an alkyl group (e.g., a CM alkyl group) that is substituted with a heteroaryl group. Both "alkyl" and "heteroaryl" have been defined above.
[0087] As used herein, "cyclic moiety" includes cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, or heteroaryl, each of which has been defined previously.
[0088] As used herein, an "acyl" group refers to a formyl group or alkyl-C(=O)- where "alkyl" has been defined previously. Acetyl and pivaloyl are examples of acyl groups.
[0089] As used herein, a "carbamoyl" group refers to a group having the structure -O-CO-
NRxRy or -NRX-CO-O-RZ wherein Rx and Ry have been defined above and Rz can be alkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroaralkyl.
[0090] As used herein, a "carboxy" and a "sulfo" group refer to -COOH and -SO3H, respectively.
[0091] As used herein, an "alkoxy" group refers to an alkyl-O- group where "alkyl" has been defined previously.
[0092] As used herein, a "sulfoxy" group refers to -O-SO-RX or -SO-O-RX, where Rx has been defined above.
[0093] As used herein, a "halogen" or "halo" group refers to fluorine, chlorine, bromine or iodine. [0094] As used herein, a "sulfamoyl" group refers to the structure -S(O)2-NRxRy or -NRX - S(O)2-R2 wherein Rx, Ry, and Rz have been defined above.
[0095] As used herein, a "sulfamide" group refers to the structure -NRX -S(O)2-NRYRZ wherein Rx, Rγ, and Rz have been defined above.
[0096] As used herein, a "urea" group refers to the structure -NRX-CO-NRYRZ and a "thiourea" group refers to the structure -NRX-CS-NRYRZ. Rx, Rγ, and Rz have been defined above. [0097] As used herein, an effective amount is defined as the amount required to confer a therapeutic effect on the treated patient, and is typically determined based on age, surface area, weight, and condition of the patient. The interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich et al., Cancer Chemother. Rep., 50: 219 (1966). Body surface area may be approximately determined from height and weight of the patient. See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardsley, New York, 537 (1970). As used herein, "patient" refers to a mammal, including a human. [0098] An antagonist, as used herein, is a molecule that binds to the receptor without activating the receptor. It competes with the endogenous ligand(s) or substrate(s) for binding site(s) on the receptor and, thus inhibits the ability of the receptor to transduce an intracellular signal in response to endogenous ligand binding.
[0099] As compounds of formula (I) are antagonists of TGF/3 receptor type I (Alk5) and/or activin receptor type I (Alk4), these compounds are useful in inhibiting the consequences of TGF/3 and/or activin signal transduction such as the production of extracellular matrix (e.g., collagen and fibronectin), the differentiation of stromal cells to myofibroblasts, and the stimulation of and migration of inflammatory cells. Thus, compounds of formula (I) inhibit pathological inflammatory and fibrotic responses and possess the therapeutic utility of treating and/or preventing disorders or diseases for which reduction of TGF/3 and/or activin activity is desirable (e.g., various types of fibrosis or progressive cancers). In addition, the compounds of formula (I) are useful for studying and researching the role of TGFjS receptor type I (Alk5) and/or activin receptor type I (Alk4), such as their role in cellular processes, for example, signal transduction, production of extracellular matrix, the differentiation of stromal cells to myofibroblasts, and the stimulation of and migration of inflammatory cells. [0100] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. [0101] Other features and advantages ot the invention will be apparent from the following detailed description, and from the claims.
DETAILED DESCRIPTION OF THE INVENTION
[0102] In general, the invention features compounds of formula (I), which exhibit surprisingly high affinitiy for the TGF β family type I receptors, AIk 5 and/or AIk 4. Synthesis of the Compounds of formula (I)
[0103] Compounds of formula (I) may be prepared by a number of known methods from commercially available or known starting materials. In one method, compounds of formula (I) are prepared according to Schemes Ia, Ib, or Ic below. Specifically, in Scheme Ia, optionally substituted 2-methylpyrimidine (II) is deprotonated by LDA before reacting with R1 -substituted carboxylic acid methoxy-methyl-amide (V) to form an R1-(6-methylpyrimidinyl)-ketone (III). R1 has been defined above. The methoxy-methyl-amide can be prepared by reacting a corresponding acid chloride (i.e., R'-CO-CI) with N, 0-dimethylhydroxylamine hydrochloride. The R1-(6-methylpyrimidinyl)-ketone (III) can then be treated with sodium nitrite in acetic acid to afford an α-keto-oxime (IV), which can undergo further reaction with an appropriate substituted (and optionally protected) aldehyde (VI) in the presence of ammonium acetate to yield a compound of formula (I).
Scheme Ia
1. NH4OAc
(IV)
(I)
[0104] In another method, the above-described compounds of formula (I) can be prepared according to Scheme Ib below. Specifically, l,l-dimethoxy-propan-2-one can first react with dimethoxymethyl-dimethyl-amine at an elevated temperature to produce the intermediate 4- dimethylamino-l,l-dimethoxy-but-3-en-2-one, which can then react with an Ra-substituted amidine to form an Ra-substituted pyrimidine-2-carbaldehyde (Ila). This carbaldehyde (Ha) can then reacted with aniline and diphenyl phosphite to form a resulting N.P-acetal, which can further couple with an R1 -substituted aldehyde to produced an (R'-methyty-pyrirnidinyl-ketone (πia). See, e.g., Journet et al., Tetrahedron Lett 39: 1717-1720 (1998). Treatment of the (R1- methyl)-pyrimidinyl-ketone (Ilia) with sodium nitrite in acetic acid produces an ce-keto-oxime (IVa), which can undergo reaction with an appropriate substituted (and optionally protected) aldehyde (VI) to yield a compound of formula (I) as described in Scheme Ia above.
Scheme Ib
(Ilia)
(Ila)
1. NH4OAc
[0105] In another methodj the above-described compounds of formula (I) can be prepared according to Scheme Ic below. Specifically, an (R'-methyty-pyrimidinyl-ketone (Ilia) (described above) can be oxidized to form a pyrimidinyl-diketone (IVb), which can undergo reaction with an appropriate substituted (and optionally protected) aldehyde (VI) to yield a compound of formula (I) as described above.
Scheme Ic
1. NH4OAc
(I)
[0106] If compound (VI) is in its protected form, appropriate deprotecting agents can be applied to the resulting compound after the coupling reaction of compound (IV) or (IVa) and compound (VI) to yield a compound of formula (I). See, e.g., T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, Inc., New York (1981), for suitable protecting groups. [0107] Alternatively, a compound of formula (I) can be prepared by reacting intermediate (IV) or (FVa) with an aldehyde (VII) to yield a further intermediate (VIII), which can then react with compound (IX) to yield a compound of formula (I). Note that moieties Y' and Y" are precursors of moiety Y. See Scheme 2 below. In addition, desired substitutions at Ra can be obtained by selecting, for example, the appropriate compound (Ha) intermediate.
Scheme 2
(I)
[0108] In some embodiments, moiety X in compound (VTI) is a nitrogen-containing heterocycloalkyl (e.g., piperidine). The nitrogen ring atom can be protected by a nitrogen protecting group (e.g., Cbz, Boc, or FMOC) before coupling to compound (IV) or (IVa) and deprotected afterwards (see first step of Scheme 3) to yield compound (Villa). This compound can further react with various compounds (IX) to produce a compound of formula (I). See second steps of Scheme 3 below. It should be noted that compound (VIII) or compound (Villa) can be a compound of formula (I) as well.
Scheme 3
(using Pd/C
(D
[0109] Similarly, when moiety X in compound (VII) is a cycloalkyl (e.g., cyclopentyl, cyclohexyl, or bicyclo[2.2.2]octane), it can be further functionalized to form a compound of formula (I) as depicted in Schemes 4, 5a, 5b, and 5c below. Scheme 4
Pd/C
Scheme 5a
(I)
(D
Scheme 5b
(I) (I)
(I) (I)
(I) (I)
(I)
(can be further modified according to Scheme 5c below)
(I)
(can be further modified according to Scheme 5c below)
(6) D RlE2AS,O T*HCFI
(I) (I)
(I)
Trifluoroactic anhydridΘ
(7) Pyridine, THF
(I) (I)
(I)
(I)
Scheme 5c
(D
[0110] As is well known to a skilled person in chemistry, desired substitutions can be placed on the pyrimidinyl ring in the last steps of the synthesis. See Scheme 6 below, for example.
Scheme 6
R2
[0111] Compounds of formula (I) wherein Rb is not hydrogen can be prepared by known methods. For example, compounds of formula (I) wherein A1 is N and A2 is NH (or vice versa) can be treated with R.1 (e.g., alkyl locude) and CSCO3 to produce a compound of formula (I) wherein Rb is alkyl. See, e.g., Liverton, et al., J. Med. Chem., 42: 2180-2190 (1999). [0112] As will be obvious to a skilled person in the art, some starting materials and intermediates may need to be protected before undergoing synthetic steps as described above. For suitable protecting groups, see, e.g., T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, Inc., New York (1981). Uses of Compounds of formula (D
[0113] As discussed above, hyperactivity of the TGF]S family signaling pathways can result in excess deposition of extracellular matrix and increased inflammatory responses, which can then lead to fibrosis in tissues and organs (e.g., lung, kidney, and liver) and ultimately result in organ failure. See, e.g., Border, W.A. and Ruoslahti E. J. CHn. Invest. 90: 1-7 (1992) and Border, W.A. and Noble, N.A. N Engl. J. Med. 331 : 1286-1292 (1994). Studies have been shown that the expression of TGFjS and/or activin mRΝA and the level of TGFjS and/or activin are increased in patients suffering from various fibrotic disorders, e.g., fibrotic kidney diseases, alcohol- induced and autoimmune hepatic fibrosis, myelofibrosis, bleomycin-induced pulmonary fibrosis, and idiopathic pulmonary fibrosis. Elevated TGFβ and/or activin is has also been demonstrated in cachexia, demyelination of neurons in multiple sclerosis, Alzheimer's disease, cerebral angiopathy and hypertension.
[0114] Compounds of formula (I), which are antagonists of the TGFjS family type I receptors AIk 5 and/or AIk 4, and inhibit TGFjS and/or activin signaling pathway, are therefore useful for treating and/or preventing fibrotic disorders or diseases mediated by an increased level of TGFjS and/or activin activity. As used herein, a compound inhibits the TGFjS family signaling pathway when it binds (e.g., with an IC50 value of less than 10 μM; such as, less than 1 /xM; and for example, less than 5 nM) to a receptor of the pathway (e.g., AIk 5 and/or AIk 4), thereby competing with the endogenous ligand(s) or substrate(s) for binding site(s) on the receptor and reducing the ability of the receptor to transduce an intracellular signal in response to the endogenous ligand or substrate binding. The aforementioned disorders or diseases include any condition (a) marked by the presence of an abnormally high level of TGFjS and/or activin; and/or (b) an excess accumulation of extracellular matrix; and/or (c) an increased number and synthetic activity of myofibroblasts. These disorders or diseases include, but are not limited to, fibrotic conditions such as scleroderma, glomerulonephritis, diabetic nephropathy, lupus nephritis, hypertension-induced nephropathy, ocular or corneal scarring, alimentary track or gastrointestinal fibrosis, renal fibrosis, hepatic or biliary fibrosis, acute lung injury, pulmonary fibrosis (such as idiopathic pulmonary fibrosis and radiation-induced pulmonary fibrosis), post- infarction cardiac fibrosis, fibrosclerosis, fibrotic cancers, fibroids, fibroma, fibroadenomas, and fibrosarcomas. Other fibrotic conditions for which preventive treatment with compounds of formula (I) can have therapeutic utility include radiation-induced fibrosis, chemotherapy- induced fibrosis, and surgically-induced scarring including surgical adhesions, laminectomy, and coronary restenosis.
[0115] Increased TGF/3 activity is also found to manifest in patients with progressive cancers. Studies have shown that in many cancers, the tumor cells, stromal cells, and/or other cells within a tumor generally overexpress TGF /3. This leads to stimulation of angiogenesis and cell motility, suppression of the immune system, and/or increased interaction of tumor cells with the extracellular matrix. See, e.g., Hojo, M. et al., Nature 397: 530-534 (1999) and Lammerts E. et al., Int. J. Cancer 102: 453-462 (2002). As a result, the tumors grow more readily, become more invasive and metastasize to distant organs. See, e.g., Maehara, Y. et al., J. CHn. Oncol. 17: 607-614 (1999) and Picon, A. et al., Cancer Epidemiol. Biomarkers Prev. 7: 497-504 (1998). Thus, compounds of formula (I), which are antagonists of the TGF/3 type I receptor and inhibit TGF/5 signaling pathways, are also useful for treating and/or preventing various cancers which overexpress TGF/3 or benefit from TGF/3's above-mentioned pro-tumor activities. Such cancers include carcinomas of the lung, breast, liver, biliary tract, gastrointestinal tract, head and neck, pancreas, prostate, cervix as well as multiple myeloma, melanoma, glioma, and glioblastomas. [0116] Importantly, it should be pointed out that because of the chronic, and in some cases localized, nature of disorders or diseases mediated by overexpression of TGF/3 and/or activin (e.g., fibrosis or cancers), small molecule treatments (such as treatment disclosed in the present invention) are favored for long-term treatment.
[0117] Not only are compounds of formula (I) useful in treating disorders or diseases mediated by high levels of TGF/3 and/or activin activity, these compounds can also be used to prevent the same disorders or diseases. It is known that polymorphisms leading to increased TGF/3 and/or activin production have been associated with fibrosis and hypertension. Indeed, high serum TGF/3 levels are correlated with the development of fibrosis in patients with breast cancer who have received radiation therapy, chronic graft-versus-host-disease, idiopathic interstitial pneumonitis, veno-occlusive disease in transplant recipients, and peritoneal fibrosis in patients undergoing continuous ambulatory peritoneal dialysis. Thus, the levels of TGF/3 and/or activin in serum and of TGF/3 and/or activin mRNA in tissue can be measured and used as diagnostic or prognostic markers for disorders or diseases mediated by overexpression of TGF/3 and/or activin, and polymorphisms in the gene for TGF/3 that determine the production of TGF/3 and/or activin can also be used in predicting susceptibility to disorders or diseases. See, e.g., Blobe, G.C. et al., N. Engl. J. Med. 342(18): 1350-1358 (2000); Matsuse, T. et al, Am. J. Respir. Cell MoI. Biol. 13: 17-24 (1995); Inoue, S. et al., Biochem. Biophys. Res. Comm. 205: 441-448 (1994); Matsuse, T. et al, Am. J. Pathol. 148: 707-713 (1996); De Bleser et al., Hepatology 26: 905-912 (1997); Pawlowski, J.E., et al., J. Clin. Invest. 100: 639-648 (1997); and Sugiyama, M. et al., Gastroenterology 114: 550-558 (1998).
ADMINISTRATION OF COMPOUNDS OF FORMULA (T)
[0118] As defined above, an effective amount is the amount required to confer a therapeutic effect on the treated patient. For a compound of formula (I), an effective amount can range, for example, from about 1 mg/kg to about 150 mg/kg (e.g., from about 1 mg/kg to about 100 mg/kg). Effective doses will also vary, as recognized by those skilled in the art, dependant on route of administration, excipient usage, and the possibility of co-usage with other therapeutic treatments including use of other therapeutic agents and/or radiation therapy. [0119] Compounds of formula (I) can be administered in any manner suitable for the administration of pharmaceutical compounds, including, but not limited to, pills, tablets, capsules, aerosols, suppositories, liquid formulations for ingestion or injection or for use as eye or ear drops, dietary supplements, and topical preparations. The pharmaceutically acceptable compositions include aqueous solutions of the active agent, in an isotonic saline, 5% glucose or other well-known pharmaceutically acceptable excipient. Solubilizing agents such as cyclodextrins, or other solubilizing agents well-known to those familiar with the art, can be utilized as pharmaceutical excipients for delivery of the therapeutic compounds. As to route of administration, the compositions can be administered orally, intranasally, transdermally, intradermally, vaginally, intraaurally, intraocularly, buccally, rectally, transmucosally, or via inhalation, implantation (e.g., surgically), or intravenous administration. The compositions can be administered to an animal (e.g., a mammal such as a human, non-human primate, horse, dog, cow, pig, sheep, goat, cat, mouse, rat, guinea pig, rabbit, hamster, gerbil, or ferret, or a bird, or a reptile, such as a lizard).
[0120] Optionally, compounds of formula (I) can be administered in conjunction with one or more other agents that inhibit the TGF/3 signaling pathway or treat the corresponding pathological disorders (e.g., fibrosis or progressive cancers) by way of a different mechanism of action. Examples of these agents include angiotensin converting enzyme inhibitors, nonsteroid and steroid anti-inflammatory agents, immunotherapeutics, chemotherapeutics, as well as agents that antagonize ligand binding or activation of the TGF/3 receptors, e.g., anti-TGF/3, anti-TGF/3 receptor antibodies, or antagonists of the TGF/3 type II receptors. Compounds of formula (I) can also be administered in conjunction with other treatments, e.g., radiation. The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims. Example 1
4-[l-Hydroxy-4-(2-methyl-pyrimidin-4-yl)-5-[l,2,4]triazoIo[l,5-a]pyridin-6-yl-lH- imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester
Synthesis of the title compound is described in parts (a)-(b) below.
(a) l-(2-Methyl-pyrimidin-4-yl)-2-[l,2,4]triazolo[l,5-a]pyridin-6-yl-ethane-l,2-dione 2- oxime (IVa)
[0121] Sodium nitrite (1.03 g, 15 mmol) was added to a solution of l-(2-methyl-pyrimidin-4- yl)-2-[l,2,4]triazolo[l,5-a]pyridin-6-yl-ethanone (prepared according to Scheme Ib above) (2.5 g, 10 mmol) in a mixture of HOAc/THF/H2O (6:4:1, 55 mL). The mixture was stirred at 0 0C for 1 hour and then room temperature for 1 hour. Solvent was removed under reduced pressure. Residue was dissolved in water and NaOH (3N) was added until the pH was greater than 8. The aqueous solution was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated to give 1.8 g (64%) of the title compound as a yellow foam.
(b) 4-[l-Hydroxy-4-(2-methyl-pyrimidin-4-yI)-5-[l,2,4]triazolo[l,5-a]pyridin-6-yI-lH- imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxyIic acid methyl ester
[0122] 4-Formyl-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester (0.170 g, 1.0 mmol) was added to a solution of l-(2-methyl-pyrimidin-4-yl)-2-[l,2,4]triazolo[l,5-a]pyridin-6-yl-ethane- 1,2-dione 2-oxime (0.282 g, 1 mmol) and ammonium acetate (1.54 g, 20 mmol) in acetic acid (5 mL). The mixture was refluxed for 3 hours. Solvent was removed under reduced pressure. The reaction mixture was then quenched with an ammonia/ice mixture. The aqueous solution was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated to give 0.40Og (87%) of the title compound as a yellow solid.
Example 2
4-[4-(2-Methyl-pyrimidin-4-yl)-5-[l,2,4]triazolo[l,5-a]pyridin-6-yl-lH-imidazol-2-yl]- bicyclo [2.2.2] octane-1-carboxylic acid methyl ester
[0123] Triethylphosphite (0.343 uL, 2.0 mmol) was added to a solution of 4-[l-hydroxy-4-(2- methyl-pyrimidin-4-yl)-5-[l,2,4]triazolo[l,5-a]pyridin-6-yl-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methyl ester (0.40 g, 0.87 mmol; see Example 1 above) in DMF (10 mL). The mixture was heated at 110 0C for 18 hours. The solvent was removed. The residue was portioned between ethyl acetate and brine. The organic layer was dried over sodium sulfate, filtered, and concentrated to give a yellow oil. HPLC purification gave 0.30 g (77%) of the title compound as a yellow oil. 1H NMR (300 MHz, Methanol-d4) δ 9.32 (s, IH), 8.69 (d, IH, J = 5.7 Hz), 8.58 (s, IH), 7.93 (m, 2H), 7.74 (d, IH, J = 5.7 Hz), 3.68 (s, 3H), 2.65 (s, 3H), 2.15 (m, 6H), 1.99 (m, 6H). MS (ES+) m/z (M+l) 444.24. Example 3
4- [4-(2-Methyl-pyrimidin-4-yl)-5- [1 ,2,4] triazolo [1 ,5-a] pyridin-6-yl-lH-imidazoI-2-yl] - bicyclo [2.2.2] octane-1-carboxylic acid
[0124] Lithium hydroxide monohydrate (0.046 g, 1.12 mmol) was added to a solution of 4-[4- (2-methyl-pyrimidin-4-yl)-5-[l,2,4]triazolo[l,5-a]pyridin-6-yl-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methyl ester (0.25 g, 0.56 mmol) in a mixture of THF/MeOH/H2O (2/1/1, 4 mL). The mixture was stirred for 3 hours, and the solvent was removed. The residue was diluted with water (30 mL). Citric acid was added to the solution to make the pH lower than 7. The aqueous solution was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated to give 0.180 g (75%) of the title compound as a yellow solid. 1H NMR (300 MHz, Methanol-d4) δ 9.29 (s, IH), 8.65 (d, IH, J = 5.4 Hz), 8.54 (s, IH), 7.91 (m, 2H), 7.67 (d, IH, J = 5.7 Hz), 2.64 (s, 3H), 2.14 (m, 6H), 2.00 (m, 6H). MS (ES+) m/z (M+l) 430.28. Example 4
4-[4-(2-Methyl-pyrimidin-4-yl)-5-[l,2,4]triazolo[l,5-a]pyridin-6-yI-lH-imidazol-2-yI]- bicyclo [2.2.2] octane-1-carboxylic acid amide
[0125] HATU (0.265 g, 0.70 mmol) was added to a solution of 4-[4-(2-methyl-pyrimidin-4-yl)- 5-[l ,2,4]triazolo[l ,5-a]pyridin-6-yl-lH-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid (0.150 g, 0.35 mmol) and potassium carbonate (0.1242 g, 1.75 mmol) in DMF (5 mL). The mixture was stirred for 10 minutes. NH3 was bubbled into the reaction mixture for 10 minutes. The mixture was stirre for an additional 2 hours. The mixture was filtered, and DMF was removed under reduced pressure. The residue was dissolved in DMSO and the DMSO solution was filtered. HPLC purification of the DMSO solution gave 0.040 g (27%) of the title compound as a yellow solid. 1H NMR (300 MHz, Methanol-d4) δ 9.30 (s, IH), 8.67 (d, IH, J = 6.0 Hz), 8.56 (s, IH), 7.92 (m, 2H), 7.69 (d, IH, J = 6.0 Hz), 2.65 (s, 3H), 2.15 (m, 6H), 1.99 (m, 6H). MS (ES+) m/z (M+l) 429.25.
Example 5
4-[4-(2-Methyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-lH-imidazol-2-yl]-bicyclo[2.2.2]octan-l- ol Synthesis of the title compound is described in parts (a)-(b) below.
(a) l-(2-Methyl-pyrimidin-4-yl)-2-quinoxalin-6-yl-ethane-l,2-dione (IVb)
[0126] To a solution of 2-(2-methyl-pyrimidin-4-yl)-l-quinoxalin-6-yl-ethanone (0.500 g, 1.9 mmol; prepared according to Scheme Ib above)) in DMSO (5 mL) was added NBS (0.337 g, 1.9 mmol) and then stirred at room temperature for 3 days. The mixture was partitioned between ether and water. Ether was washed with brine, dried over sodium sulfate, filtered and concentrated to give 0.200 g (38%) of l-(2-methyl-pyrimidin-4-yl)-2-quinoxalin-6-yl-ethane- 1 ,2-dione as a yellow solid.
(b) 4-[4-(2-MethyI-pyrimidin-4-yl)-5-quinoxalin-6-yl-lH-imidazol-2-yl]-bicyclo[2.2.2]octan- l-ol
[0127] 4-Hydroxy-bicyclo[2.2.2]octane-l-carbaldehyde (0.130 g, 0.86 mmol) was added to a solution of l-(2-methyl-pyrimidin-4-yl)-2-quinoxalin-6-yl-ethane-l,2-dione (0.200 g, 0.72 mmol) and ammonium acetate (0.554 g, 7.2 mmol) in acetic acid (10 mL). The mixture was reflux for 3 hours. Solvent was removed under reduced pressure. Reaction mixture was then quenched with ammonia/ice mixture. The aqueous solution was extracted with ethyl acetate. Ethyl acetate was washed with brine, dried over sodium sulfate, filtered, and concentrated. HPLC purification eluting with acetonitrile:water gave 0.06 g (20%) of the title compound as a yellow solid. 1H NMR (300 MHz, Methanol^) δ 8.99 (m, 2H), 8.63 (d, IH, J = 5.8 Hz), 8.43 (d, IH, J = 1.8 Hz), 8.25 (d, IH, J = 8.7 Hz), 8.03 (m, IH), 7.47 (d, IH, J = 5.7 Hz), 2.30 (m, 6H), 1.87 (m, 6H). MS (ES+) m/z (M+l) 413.28.
Example 6
4-[l-Hydroxy-4-(6-methyl-pyridin-2-yl)-5-(2-methylsulfanyI-pyrimidin-4-yl)-lH-imidazol- 2-yl]-bicyclo [2.2.2] octane-l-carboxylic acid methyl ester
Synthesis of the title compound is described in parts (a)-(b) below. (a) l-(6-Methyl-pyridin-2-yl)-2-(4-methyIsulfanyl-pyrimidin-2-yl)-ethane-l,2-dione 2- oxime (IV)
[0128] Sodium nitrite (0.479 g, 6.9 mmol) was added to a solution of l-(6-methyl-pyridin-2-yl)- 2-(4-methylsulfanyl-pyrimidin-2-yl)-ethanone (1.2 g, 4.6 mmol; prepared according to Scheme 1 above) in a mixture of HOAc/THF/H2O (6:4:1, 35 mL). The mixture was stirred at 00C for 1 hour and then at room temperature for another hour. Solvent was removed under reduced pressure. Residue was dissolved in water, to which NaOH (3N) was added until pH was larger than 8. The aqueous solution was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated to give 1.3 g (98%) of the title oxime as a yellow foam.
(b) 4-[l-Hydroxy-4-(6-methyl-pyridin-2-yl)-5-(2-methyIsulfanyl-pyrimidin-4-yl)-lH- imidazol-2-yl]-bicyclo [2.2.2] octane-1-carboxylic acid methyl ester
[0129] 4-Formyl-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester (0.72 g, 2.5 mmol) was added to a solution of l-(6-methyl-pyridin-2-yl)-2-(4-methylsulfanyl-pyrimidin-2-yl)-ethane-
1,2-dione 2-oxime (0.6 g, 2.1 mmol) and ammonium acetate (3.1 g, 40 mmol) in acetic acid (30 mL). The mixture was reflux for 2 hours. Solvent was removed under reduced pressure.
Reaction mixture was then quenched with ammonia/ice mixture. The aqueous solution was extracted with ethyl acetate. Ethyl acetate was washed with brine, dried over sodium sulfate, filtered, and concentrated to 0.9 g (92%) of the title methyl ester as a yellow solid.
Example 7
4-[4-(6-MethyI-pyridin-2-yl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-lH-imidazol-2-yl]- bicyclo [2.2.2] octane-1-carboxylic acid methyl ester
[0130] Trimethylphosphite (1.0 mL, 9.7 mmol) was added to a solution of 4-[l-hydroxy-4-(6- methyl-pyridin-2-yl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methyl ester (0.9 g, 1.93 mmol; see Example 6 above) in
DMF (10 mL). The mixture was stirred at 1100C for 18 hours. Solvent was removed to give a yellow oil. Column chromatography eluting with ethyl acetate:hexanes (50:50) gave 0.8 g
(97%) of the title compound as a yellow solid. 1H NMR (300 MHz, DMSOd6) δ 12.25 (s, IH),
8.51 (m, IH), 7.71 (m, 2H), 7.59 (d, IH, J = 6.0 Hz), 7.22 (t, IH, J = 3.0 Hz), 3.61 (s, 3H), 3.29
(s, 3H), 2.11 (s, 3H), 1.98 (m, 6H), 1.83 (m, 6H). MS (ES+) m/z (M+l) 450.15.
Example 8
4- [5-(2-Methanesulfonyl-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-l H-imidazol-2-yl] - bicyclo [2.2.2] octane-1-carboxylic acid methyl ester
[0131] Hydrogen peroxide (0.19 mL,6.68 mmol), 4N H2SO4 (0.06 mL), and NaWO4H2O (10 mg) were added to a solution of 4-[4-(6-methyl-pyridin-2-yl)-5-(2-methylsulfanyl-pyrimidin-4- yl)-lH-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester (0.60 g, 1.34 mmol; see Example 7 above) in methonal (20 mL). The mixture was stirred at 500C for 10 hours. The mixture was then quenched with water and stirred for 30 minutes. Saturated Na2S2O3 aqueous solution was added to neutralize the excess hydrogen peroxide. The aqueous solution was extracted with ethyl acetate. Ethyl acetate was washed with brine, dried over sodium sulfate, filtered, and concentrated. Column chromatography eluting with ethyl acetate gave 0.5 g (91%) of the title compound as a yellow solid. 1H NMR (300 MHz, Methanol-d4) δ 8.98 (m, IH), 8.43
(m, IH), 8.22 (m, IH), 8.09 (m, IH), 7.84 (m, IH), 3.68 (s, 3H), 3.26 (s, 3H), 2.86 (s, 3H), 2.11 (m, 6h), 1.99 (m, 6H). MS (ES+) m/z (M+l) 482.02. Example 9
4-[5-(2-Methanesulfonyl-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yI]- bicyclo [2.2.2] octane-1-carboxylic acid methyl ester
[0132] 4-[5-(2-Methanesulfonyl-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-iniidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methyl ester (0.30 g, 0.62 mmol; see Example 8 above) was dissolved in cyclopropylamine (10 mL) and the mixture was placed in a sealed tube. The mixture was heated at 800C for 18 hours. Solvent was removed to give 0.285 g (99%) of the title compound as a yellow solid. 1H NMR (300 MHz, Acetone-de) δ 8.56 (m, IH), 8.49 (m, IH), 8.24 (m, IH), 7.65 (m, 2H), 3.63 (s, 3H), 2.87 (m, IH), 2.61 (s, 3H), 2.05 (m, 6H), 1.91 (m, 6H), 0.75 (m, 2H), 0.64 (m, 2H). MS (ES+) m/z (M+l) 459.17. Example 10
4-[5-(2-Cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridm-2-yl)-lH-imidazol-2-yl]- bicyclo [2.2.2] octane-1-carboxylic acid
[0133] Lithium hydroxide monohydrate (0.10 g, 2.44 mmol) was added to 4-[5-(2- Cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methyl ester (0.28 g, 0.61 mmol) in a mixture of THFMeOHTH2O (2/1/1, 5 mL). The mixture was stirred for 3 h. Solvent was removed. Residue was diluted with water (30 mL). Citric acid was added to the solution to make the pH lower than 7. The aqueous solution was extracted with ethyl acetate. Ethyl acetate was washed with brine, dried over sodium sulfate, filtered and concentrated to give 0.27 g (99%) of the title compound as a yellow solid. 1H NMR (300 MHz, Methanol-d*) δ 8.50 (m, IH), 8.29 (m, 2H), 7.66 (m, IH), 7.30 (m, IH), 2.75 (m, IH), 2.65 (s, 3H), 2.07 (m, 6H), 1.97 (m, 6H), 0.86 (m, 2H), 0.62 (m, 2H). MS (ES+) m/z (M+l) 445.10. Example 11
4-[5-(2-Cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo [2.2.2] octane-1-carboxylic acid amide
[0134] HATU (0.17 g, 0.45 mmol) was added to a solution of 4-[5-(2-Cyclopropylamino- pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid (0.10 g, 0.225 mmol; see Example 10 above) and potassium carbonate (0.155 g, 1.13 mmol) in anhydrous DMF (5 mL). The mixture was stirred for 30 minutes. Ammonia was bubbled through the mixture for 10 minutes. The mixture was continued to stir for 2 hours. The mixture was then filtered and concentrated. HPLC purification eluting with acetonitrile: water gave 0.070 g (70%) of the title compound as a yellow solid. 1H NMR (300 MHz, Methanol-d4) δ 8.50 (d, IH, J = 5.7 Hz), 8.30 (m, 2H), 7.67 (m, IH), 7.32 (d, IH, J = 5.7 Hz), 2.75 (m, IH), 2.65 (s, 3H), 2.08 (m, 6H), 1.95 (m, 6H), 0.84 (m, 2H), 0.61 (m, 2H). MS (ES+) m/z (M+l) 444.21. [0135] The compounds listed in the following Table were prepared in an analogous manner to those described in the methods and examples above.
[0136] The TGF/3 inhibitory activity of compounds of formula (I) can be assessed by methods described in the following examples.
Example 34
Cell-Free Assay for Evaluating Inhibition of Autophosphorylation of TGFjS Type I
Receptor
[0137] The serine-threonine kinase activity of TGFjS type I receptor was measured as the autophosphorylation activity of the cytoplasmic domain of the receptor containing an N-terminal poly histidine, TEV cleavage site-tag, e.g., His-TGF/3RI. The His-tagged receptor cytoplasmic kinase domains were purified from infected insect cell cultures using the Gibco-BRL FastBac
HTb baculovirus expression system.
[0138] To a 96-well Nickel FlashPlate (NEN Life Science, Perkin Elmer) was added 20 μL of
1.25 μCi 33P- ATP/25 μM ATP in assay buffer (50 mM Hepes, 60 mM NaCl, 1 mM MgCl2, 2 mM DTT, 5 mM MnCl2, 2% glycerol, and 0.015% Brij® 35). 10 μL of each test compound of formula (I) prepared in 5% DMSO solution were added to the FlashPlate. The assay was then initiated with the addition of 20 μL of assay buffer containing 12.5 pmol of His-TGFβRI to each well. Plates were incubated for 30 minutes at room temperature and the reactions were then terminated by a single rinse with TBS. Radiation from each well of the plates was read on a
TopCount (Packard). Total binding (no inhibition) was defined as counts measured in the presence of DMSO solution containing no test compound and non-specific binding was defined as counts measured in the presence of EDTA or no-kinase control.
[0139] Alternatively, the reaction performed using the above reagents and incubation conditions but in a microcentrifuge tube was analyzed by separation on a 4-20% SDS-PAGE gel and the incorporation of radiolabel into the 40 kDa His-TGFβRI SDS-PAGE band was quantitated on a
Storm Phosphoimager (Molecular Dynamics).
[0140] Compounds of formula (I) typically exhibited IC50 values of less than 10 μM; some exhibited IC50 values of less than 1 μM; and some even exhibited IC50 values of less than 50 nM.
Example 35
Cell-Free Assay for Evaluating Inhibition of Activin Type I Receptor Kinase Activity
[0141] Inhibition of the Activin type I receptor (AIk 4) kinase autophosphorylation activity by test compounds of formula (I) can be determined in a similar manner to that described above in Example 34 except that a similarly His-tagged form of AIk 4 (His-Alk 4) is used in place of the
Example 36
TGFjS Type I Receptor Ligand Displacement FIashPlate Assay
[0142] 50 nM of tritiated 4-(3-pyridin-2-yl-lH-pyrazol-4-yl)-quinoline (custom-ordered from PerkinElmer Life Science, Inc., Boston, MA) in assay buffer (50 mM Hepes, 60 mM NaCl2, 1 mM MgCl2, 5 mM MnCl2, 2 mM 1,4-dithiothreitol (DTT), 2% Brij® 35; pH 7.5) was premixed with a test compound of formula (I) in 1% DMSO solution in a v-bottom plate. Control wells containing either DMSO without any test compound or control compound in DMSO were used. To initiate the assay, His-TGFjS Type I receptor in the same assay buffer (Hepes, NaCl2, MgCl2, MnCl2, DTT, and 30% Brij® added fresh) was added to a nickel coated FIashPlate (PE, NEN catalog number: SMP107), while the control wells contained only buffer (i.e., no His-TGF/3 Type I receptor). The premixed solution of tritiated 4-(3-pyridin-2-yl-lH-pyrazol-4-yl)- quinoline and test compound of formula (I) was then added to the wells. The wells were aspirated after an hour at room temperature and radioactivity in wells (emitted from the tritiated compound) was measured using TopCount (PerkinElmer Lifesciences, Inc., Boston MA). Compounds of formula (I) typically exhibited K; values of less than 10 μM; some exhibited K; values of less than 1 μM; and some even exhibited Kj values of less than 50 nM. Example 37
Assay for Evaluating Cellular Inhibition of TGF/S Signaling and Cytotoxicity [0143] Biological activity of the compounds of formula (I) was determined by measuring their ability to inhibit TGF/3-induced PAI-Luciferase reporter activity in HepG2 cells. [0144] HepG2 cells were stably transfected with the PAI-luciferase reporter grown in DMEM medium containing 10% FBS, penicillin (100 U/mL), streptomycin (100 μg/mL), L-glutamine (2 mM), sodium pyruvate (1 mM), and non-essential amino acids (Ix). The transfected cells were then plated at a concentration of 2.5 x 104 cells/well in 96 well plates and starved for 3-6 hours in media with 0.5% FBS at 37 0C in a 5% CO2 incubator. The cells were then stimulated with 2.5 ng/mL TGF/3 ligand in the starvation media containing 1% DMSO either in the presence or absence of a test compound of formula (I) and incubated as described above for 24 hours. The media was washed out the following day and the luciferase reporter activity was detected using the LucLite Luciferase Reporter Gene Assay kit (Packard, cat. no. 6016911) as recommended. The plates were read on a Wallac Microbeta plate reader, the reading of which was used to determine the IC50 values of" compounds of formula (I) for inhibiting TGF/3-induced
PAI-Luciferase reporter activity in HepG2 cells. Compounds of formula (I) typically exhibited
IC50 values of less 10 μM.
[0145] Cytotoxicity was determined using the same cell culture conditions as described above.
Specifically, cell viability was determined after overnight incubation with the CytoLite cell viability kit (Packard, cat. no. 6016901). Compounds of formula (I) typically exhibited LD25 values greater than 10 μM.
Example 38
Assay for Evaluating Inhibition of TGFβ Type I Receptor Kinase Activity in Cells
[0146] The cellular inhibition of activin signaling activity by the test compounds of formula (I) is determined in a similar manner as described above in Example 37 except that 100 ng/mL of activin is added to serum starved cells in place of the 2.5 ng/mL TGF/3.
Example 39
Assay for TGF/3-Induced Collagen Expression
Preparation of Immortalized Collagen Promotor-Green Fluorescent Protein Cells
[0147] Fibroblasts are derived from the skin of adult transgenic mice expressing Green
Fluorescent Protein (GFP) under the control of the collagen IAl promoter (see Krempen, K. et al., Gene Exp. 8: 151-163 (1999)). Cells are immortalized with a temperature sensitive large T antigen that is in an active stage at 33 0C. Cells are expanded at 33 0C and then transferred to 37
0C at which temperature the large T antigen becomes inactive (see Xu, S. et al., Exp. Cell Res.
220: 407-414 (1995)). Over the course of about 4 days and one split, the cells cease proliferating. Cells are then frozen in aliquots sufficient for a single 96 well plate.
Assay ofTGFβ-induced Collagen-GFP Expression
[0148] Cells are thawed, plated in complete DMEM (contains non-essential amino acids, ImM sodium pyruvate and 2mM L-glutamine) with 10 % fetal calf serum, and then incubated for overnight at 37 0C, 5% CO2. The cells are trypsinized in the following day and transferred into
96 well format with 30,000 cells per well in 50 μL complete DMEM containing 2 % fetal calf serum, but without phenol red. The cells are incubated at 37 0C for 3 to 4 hours to allow them to adhere to the plate. Solutions containing a test compound of formula (I) are then added to wells with no TGF/3 (in triplicates), as well as wells with 1 ng/mL TGF/3 (in triplicates). DMSO is also added to all of the wells at a final concentration of 0.1%. GFP fluorescence emission at 530 nm following excitation at 485 ran is measured at 48 hours after the addition of solutions containing a test compound on a CytoFluor microplate reader (PerSeptive Biosystems). The data are then expressed as the ratio of TGF/3-induced to non-induced for each test sample. OTHER EMBODIMENTS
[0149] It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims

What is claimed is:
1. A compound of the following formula:
or an N-oxide or a pharmaceutically acceptable salt thereof, wherein
R1 is heteroaryl; each Ra, independently, is alkyl, alkenyl, alkynyl, alkoxy, acyl, halo, hydroxy, amino, nitro, oxo, thioxo, cyano, guanadino, amidino, carboxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkoxycarbonyl, alkylcarbonyloxy, urea, thiourea, sulfamoyl, sulfamide, carbamoyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfanyl, cycloalkylcarbonyl, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylsulfanyl, heterocycloalkylcarbonyl, aryl, aryloxy, arylsulfanyl, aroyl, heteroaryl, heteroaryloxy, heteroarylsulfanyl, or heteroaroyl;
X is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or a bond;
Y is a bond, -C(O)-, -C(O)-O-, -O-C(O)-, -S(O)P-O-, -O-S(O)P-, -C(O)-N(Rb)-, -N(Rb)-C(O)-, -O-C(O)-N(Rb)-, -N(Rb)-C(O)-O-, -C(O)-N(Rb)-O-, -O-N(Rb)-C(O)-, -O-S(O)p-N(Rb)-, -N(Rb)- S(O)p-O-, -S(O)p-N(Rb)-O-, -O-N(Rb)-S(O)p-, -N(Rb)-C(O)-N(Rc)-, -N(Rb)-S(O)p-N(Rc)-, -C(O)-N(Rb)-S(O)p-, -S(O)p-N(Rb)-C(O)-, -C(O)-N(Rb)-S(O)p-N(Rc)-, -C(O)-O-S(O)p-N(Rb)-, -N(Rb)-S(O)p-N(Rc)-C(O)-, -N(Rb)-S(O)p-O-C(O)-, -S(O)p-N(Rb)-, -N(Rb)-S(O)p-, -N(Rb)-, -S(0)p-, -0-, -S-, or -(C(Rb)(Rc))q-, wherein each of Rb and Rc, independently, is hydrogen, hydroxy, alkyl, alkoxy, amino, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroaralkyl; p is 1 or 2; and q is 1-4; R2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl,
(cycloalkenyl)alkyl, aryl, aralkyl, arylalkenyl, heterocycloalkyl, (heterocycloalkyl)alkyl, heterocycloalkenyl, (heterocycloalkenyl)alkyl, heteroaryl, heteroaralkyl, or
(heteroaryl)alkenyl; each of A and A , independently, is N or NR ; and m is 0, 1, 2, or 3; provided that when m ≥2, two adjacent Ra groups can join together to form a 4- to 8-membered optionally substituted cyclic moiety, and further provided that if
X is a bond, then Y is a bond; R2 is hydrogen or alkyl; m is 1, 2, or 3; and at least one Ra is substituted at the 2-pyrimidinyl position.
2. The compound of claim 1, wherein X is aryl or heteroaryl.
3. The compound of claim 2, wherein X is an optionally substituted phenyl.
4. The compound of claim 2, wherein Y is a bond, -N(Rb)-C(O)-, -N(Rb)-S(O)2-, -C(O)-, -C(O)-O-, -0-C(O)-, -C(0)-N(Rb)-, -S(OV, -O-, -S(0)2-N(Rb)-, - N(Rb)-, -N(Rb)-C(0)-0-, -N(Rb)-C(0)-N(Rc)-, -C(O)-N(Rb)-S(O)p-N(Rc)-, or -C(0)-0-S(0)p-N(Rb)-.
5. The compound of claim 2, wherein R2 is hydrogen, C1-6 alkyl, aryl, heteroaryl, aryl-C1-4 alkyl, or heteroaryl-C1-4 alkyl.
6. The compound of claim 1, wherein X is a 4- to 8-membered monocyclic or bicyclic cycloalkyl or heterocycloalkyl.
7. The compound of claim 1, wherein X is piperidinyl, piperazinyl, pyrrolidinyl, tetrahydrofuran, cyclohexyl, cyclopentyl, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.1]octane, 2-oxa-bicyclo[2.2.2]octane, 2-aza-bicyclo[2.2.2]octane, 3-aza-bicyclo[3.2.1]octane, or l-aza-bicyclo[2.2.2]octane.
8. The compound of claim 1, wherein X is piperidinyl, piperazinyl, or pyrrolidinyl.
9. The compound of claim 8, wherein the piperdinyl, piperazinyl, or pyrrolidinyl is bonded to Y via its nitrogen ring atom.
10. The compound of claim 9, wherein Y is a bond, -C(O)O-, -C(O)-N(Rb)-, -S(O)2-, or -S(O)2-N(Rb)-, wherein Rb is hydrogen or C1-4 alkyl.
11. The compound of claim 1, wherein X is cyclohexyl, cyclopentyl, or bicyclo[2.2.2]octane.
12. The compound of claim 11, wherein Y is -N(Rb)-C(O)-, -N(Rb)-S(O)2-, -C(O)-, -C(O)-O-, -O-C(O)-, -C(O)-N(Rb)-, -S(O)p-, -O-, -S(0)2-N(Rb)-, - N(Rb)-, -N(Rb)-C(O)-O-, -C(0)-N(Rb)-0-, or -N(Rb)-C(O)-N(Rc)-.
13. The compound of claim 1, wherein Y is -N(Rb)-C(0)-, -N(Rb)-S(O)2-, -C(O)-, -C(O)-O-, -O-C(O)-, -C(0)-N(Rb)-, -S(O)p-, -0-, -S(O)2-N(Rb)-, - N(Rb)-, -N(Rb)-C(0)-0-, -C(O)- N(Rb)-0-, -N(Rb)-C(0)-N(Rc)-, -C(0)-N(Rb)-S(0)p-N(R°)-, or -C(O)-O-S(O)p-N(Rb)-.
14. The compound of claim 1, wherein X and Y are each a bond; R2 is hydrogen or C1-6 alkyl; m is 1 or 2; and the Ra that is substituted at the 2-pyrimidinyl position is C1-4 alkyl, C3-6 cycloalkyl, or amino.
15. The compound of claim 14, wherein R2 is H or C1-4 alkyl; m is 1; and Ra is -CH3, -CF3, cyclopropyl, -NH2, -NH-C1-4 alkyl, or -NH-cycloalkyl.
16. The compound of claim 1, wherein R2 is hydrogen, C1-6 alkyl, aryl, heteroaryl, aryl-C1-4 alkyl, or heteroaryl-C1-4 alkyl.
17. The compound of claim 1, wherein R2 is hydrogen, C1-4 alkyl, phenyl, pyridyl, imidazolyl, furanyl, thienyl, triazolyl, tetrazolyl, benzyl, phenylethyl, benzimidazolyl, benzothiazolyl, naphthylmethyl, naphthylethyl, or -C1-2 alkyl-pyridyl; each of which, independently, is optionally substituted with one or more substituents selected from the group consisting of fluoro, chloro, trifluoromethyl, methyl, ethyl, aminocarbonyl, alkylcarbonylamino, sulfamoyl, alkoxycarbonyl, and alkylcarbonyloxy.
18. The compound of claim 1, wherein R2 is hydrogen, methyl, ethyl, n-butyl, t-butyl, benzyl or pyridylmethyl.
19. The compound of claim 1, wherein R1 is benzo[l,3]dioxolyl, benzo[£]thiophenyl, benzo-oxadiazolyl, benzothiadiazolyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, 2-oxo-benzooxazolyl, pyridyl, pyrimidinyl, 2,3-dihydro-benzo[l,4]dioxyl, 2,3-dihydro-benzofuryl, 2,3-dihydro-benzo[έ]thiophenyl, 3,4-dihydro-benzo[l,4]oxazinyl, 3-oxo-benzo[l,4]oxazinyl, l,l-dioxo-2,3-dihydro- benzo[ό]thiophenyl, [l,2,4]triazolo[l,5-a]pyridyl, [l,2,4]triazolo[4,3-a]pyridyl, quinolinyl, quinoxalinyl, quinazolinyl, isoquinolinyl, or cinnolinyl.
20. The compound of claim 1, wherein m is 0-2.
21. The compound of claim 1, wherein Ra is substituted at the 2-pyrimidinyl position.
22. The compound of claim 1, wherein Ra is C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, halo, amino, aminocarbonyl, or alkoxycarbonyl.
23. The compound of claim 1, wherein Rb is hydrogen or C1-4 alkyl.
24. The compound of claim 1, wherein m is 0-2; R1 is heteroaryl; R2 is hydrogen, C1-6 alkyl, aryl, heteroaryl, -C1-4 alkyl-aryl, or -C1-4 alkyl-heteroaryl; X is a 4- to 8-membered monocyclic or bicyclic cycloalkyl or heterocycloalkyl; and Y is -N(Rb)-C(O)-, -N(Rb)-S(O)2-, -C(O)-, -C(O)-O-, -O-C(O)-, -C(O)-N(Rb)-, -S(O)P-, -O-, -S(O)2-N(Rb)-, -N(Rb)-, -N(Rb)-C(O)-O-, -N(Rb)-C(O)-N(Rc)-, -C(O)-N(Rb)-S(O)p-N(Rc)-, or -C(O)-O-S(O)p-N(Rb)-.
1 0
25. The compound of claim 1, wherein m is 0-2; R is heteroaryl; R is hydrogen, C1-6 alkyl, aryl, heteroaryl, -C1-4 alkyl-aryl, or -C1-4 alkyl-heteroaryl; X is piperidinyl, piperazinyl, pyrrolidinyl, tetrahydrofuran, cyclohexyl, cyclopentyl, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.1]octane, 2-oxa-bicyclo[2.2.2]octane, 2-aza-bicyclo[2.2.2]octane, 3-aza-bicyclo[3.2.1]octane, or l-aza-bicyclo[2.2.2]octane; and Y is -N(Rb)-C(O)-, -N(Rb)-S(O)2-, -C(O)-, -C(O)-O-, -0-C(O)-, -C(0)-N(Rb)-, -S(O)P-, -O-, -S(O)2-N(Rb)-, - N(Rb)-, -N(Rb)-C(0)-0-, -N(Rb)-C(O)-N(Rc)-, -C(O)-N(Rb)-S(O)p-N(Rc)-, or -C(O)-O-S(O)p-N(Rb)-.
26. The compound of claim 1, wherein m is 0-2; R1 is heteroaryl; R2 is hydrogen, C1-6 alkyl, aryl, heteroaryl, -C1-4 alkyl-aryl, or -C1-4 alkyl-heteroaryl; and -X-Y- is
27. The compound of claim 26, wherein A1 is N and A2 is NH, or A1 is NH and A2 is N.
28. The compound of claim 27, wherein R2 is hydrogen, C1-4 alkyl, benzyl, or pyridylmethyl.
29. The compound of claim 28, wherein m is 1 and Ra is substituted at the 2-pyrimidinyl position.
30. The compound of claim 1, wherein m is 0-2; R1 is heteroaryl; R2 is hydrogen, C1-6 alkyl, aryl, heteroaryl, aryl-C1-4 alkyl, or heteroaryl-C1-4 alkyl; X is cyclohexyl, cyclopentyl, or bicyclo[2.2.2]octane; and Y is -N(Rb)-C(0)-, -N(Rb)-S(O)2-, -C(O)-, -C(O)-O-, -O-C(O)-, -C(0)-N(Rb)-, -S(OV, -O-, -S(O)2-N(Rb)-, - N(Rb)-, -N(Rb)-C(0)-0-, -N(Rb)-C(O)-N(Rc)-, -C(O)-N(Rb)-S(O)p-N(Rc)-, or -C(O)-O-S(O)p-N(Rb)-, wherein each of Rb and Rc, independently, is hydrogen or C1-4 alkyl.
31. The compound of claim 30, wherein A1 is N and A2 is NH, or A1 is NH and A2 is N.
32. The compound of claim 31, wherein R2 is hydrogen, C1-4 alkyl, benzyl, or pyridylmethyl.
33. The compound of claim 32, wherein m is 1 and Ra is substituted at the 2-pyrimidinyl position.
34. The compound of claim 1, wherein X and Y are each a bond; R2 is hydrogen or C1-4 alkyl; m is 1; Ra is -CH3, -CF3, cyclopropyl, -NH2, -NH-C1-4 alkyl, or -NH-cycloalkyl; and R1 is benzo[l,3]dioxolyl, benzo[ό]thiophenyl, benzo-oxadiazolyl, benzothiadiazolyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, 2-oxo-benzooxazolyl, pyridyl, pyrimidinyl, 2,3-dihydro-benzo[l,4]dioxyl, 2,3-dihydro-benzofuryl, 2,3-dihydro-benzo[έ]thiophenyl,
3 ,4-dihydro-benzo [ 1 ,4] oxazinyl, 3-oxo-benzo[ 1 ,4]oxazinyl, 1 , 1 -dioxo-2,3 -dihydro- benzo[δ]thiophenyl, [l,2,4]triazolo[l,5-a]pyridyl, [l,2,4]triazolo[4,3-a]pyridyl, quinolinyl, quinoxalinyl, quinazolinyl, isoquinolinyl, or cinnolinyl.
35. The compound of claim 1, wherein the compound is selected from the group consisting of:
4- [4-benzo [ 1 ,3] dioxol-5-yl-5-(2-methylsulfanyl-pyrimidin-4-yl)- 1 H-imidazol-2-yl] - benzamide;
4-[4-benzo[l,3]dioxol-5-yl-5-(2-methylsulfanyl-pyrimidin-4-yl)-lH-imidazol-2-yl]- benzonitrile;
4-[5-(2-methanesulfonyl-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methyl ester;
4-[5-(2-methoxy-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methyl ester;
4-[5-(2-hydroxy-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methyl ester;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methyl ester;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo [2.2.2] octane- 1 -carboxylic acid;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid amide; 4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid hydroxyamide;
4-[5-(2-cyclopropylammo-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methoxy-amide;
4- [5 -(2-amino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)- 1 H-imidazol-2-yl] - bicyclo [2.2.2] octane- 1 -carboxylic acid;
{4-[5-(2-cyclopropylaniino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2- yl]-bicyclo[2.2.2]oct-l-yl}-carbamic acid benzyl ester;
N-{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2- yl]-bicyclo[2.2.2]oct-l-yl}-acetamide;
N-{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridm-2-yl)-lH-imidazol-2- yl]-bicyclo[2.2.2]oct-l-yl}-methanesulfonamide;
N-{4-[5-(2-cyclopropylammo-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-iniidazol-2- yl]-bicyclo[2.2.2]oct-l-yl}-2,2,2-trifluoro-acetamide;
4-[5-quinoxalm-6-yl-4-(2-trifluoromethyl-pyrimidin-4-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octan-l-ol;
4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-qumoxalin-6-yl-lH-imidazol-2-yl]- bicyclo[2.2.2]octan-l-ol;
6-[2-tert-butyl-5-(2-cyclopropyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
6-[5-(2-byclopropyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
{4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-lH-imidazol-2-yl]- bicyclo[2.2.2]oct- 1 -yl} -methanol;
6-[5-(2-trifluoromethyl-pyriniidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
6-[2-tert-butyl-5-(2-trifluoromethyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
4-[5-quinoxalin-6-yl-4-(2-trifluoromethyl-pyrimidin-4-yl)-lH-imidazol-2-yl]-piperidine-
1 -carboxylic acid benzyl ester;
4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-lH-imidazol-2-yl]-piperidine-l- carboxylic acid benzyl ester;
6-[5-(2-cyclopropyl-pyrimidin-4-yl)-2-(l-metrianesulfonyl-piperidin-4-yl)-3H-imidazol-
4-yl] -quinoxaline;
4-[5-(2-methyl-pyrimidin-4-yl)-4-[l,2,4]triazolo[4,3-a]pyridin-6-yl-lH-imidazol-2-yl]- bicyclo[2.2.2]octan-l-ol; 4-[4-(2-methyl-pyrimidm-4-yl)-5-[l,2,4]triazolo[l,5-a]pyridin-6-yl-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid amide;
4-[4-(2-methyl-pyrimidin-4-yl)-5-[l,2,4]triazolo[l,5-a]pyridin-6-yl-lH-imidazol-2-yl]- bicyclo [2.2.2] octane- 1 -carboxylic acid;
4- [4-(2-methyl-pyrimidin-4-yl)-5 - [ 1 ,2,4] triazolo [ 1 ,5 -a]pyridin-6-yl- 1 H-imidazol-2-yl] - bicyclo[2.2.2]octane-l-carboxylic acid methyl ester;
4-[4-(2-methyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-lH-imidazol-2-yl]-cyclohexanol; and
4-[4-(2-methyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-lH-imidazol-2-yl]-bicyclo[2.2.2]octan- l-ol.
36. The compound of claim 1, wherein the compound is selected from the group consisting of:
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methyl ester;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo [2.2.2] octane- 1 -carboxylic acid;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid amide;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid hydroxyamide;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridm-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methoxy-amide;
4-[5-(2-amino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid;
N-{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2- yl]-bicyclo[2.2.2]oct-l-yl}-acetamide;
N-{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2- yl] -bicyclo [2.2.2] oct- 1 -yl } -methanesulfonamide ;
N-{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-lH-imidazol-2- yl]-bicyclo[2.2.2]oct-l-yl}-2,2,2-trifluoro-acetamide;
6-[2-tert-butyl-5-(2-trifluoromethyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
6-[5-(2-byclopropyl-pyrimidm-4-yl)-3H-imidazol-4-yl]-quinoxaline; 6-[2-tert-butyl-5-(2-cyclopropyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
6-[5-(2-cyclopropyl-pyrimidin-4-yl)-2-(l-methanesulfonyl-piperidin-4-yl)-3H-imidazol-
4-yl] -quinoxaline;
6-[5-(2-trifluoromethyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
{4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-lH-imidazol-2-yl]- bicyclo[2.2.2]oct-l-yl}-methanol;
4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-lH-imidazol-2-yl]- bicyclo[2.2.2]octan-l-ol;
4-[4-(2-methyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-lH-imidazol-2-yl]-bicyclo[2.2.2]octan- l-ol;
4-[4-(2-methyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-lH-imidazol-2-yl]-cycloliexanol;
4-[4-(2-metb.yl-pyrimidin-4-yl)-5-[l,2,4]triazolo[l,5-a]pyridin-6-yl-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid amide;
4-[4-(2-meth.yl-pyrimidin-4-yl)-5-[l,2,4]triazolo[l,5-a]pyridin-6-yl-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid;
4-[4-(2-methyl-pyrimidin-4-yl)-5-[l,2,4]triazolo[l,5-a]pyridin-6-yl-lH-imidazol-2-yl]- bicyclo[2.2.2]octane-l-carboxylic acid methyl ester; and
4-[5-(2-methyl-pyrimidin-4-yl)-4-[l,2,4]triazolo[4,3-a]pyridin-6-yl-lH-imidazol-2-yl]- bicyclo[2.2.2]octan-l-ol.
37. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
38. A pharmaceutical composition comprising a compound of claim 35 and a pharmaceutically acceptable carrier.
39. A method of inhibiting the TGF/3 signaling pathway in a subject, comprising administering to the subject an effective amount of a compound of claim 1.
40. A method of inhibiting the TGF/3 signaling pathway in a subject, comprising administering to the subject an effective amount of a compound of claim 35.
41. A method of inhibiting the TGF/3 type I receptor in a cell, comprising contacting the cell with an effective amount of a compound of claim 1.
42. A method of inhibiting the TGF/3 type I receptor in a cell, comprising contacting the cell with an effective amount of a compound of claim 35.
43. A method of reducing the accumulation of excess extracellular matrix induced by TGF/3 in a subject, comprising administering to the subject an effective amount of a compound of claim 1.
44. A method of reducing the accumulation of excess extracellular matrix induced by TGF/3 in a subject, comprising administering to the subject an effective amount of a compound of claim 35.
45. A method of treating or preventing fibrotic condition in a subject, comprising administering to the subject an effective amount of a compound of claim 1.
46. A method of treating or preventing fibrotic condition in a subject, comprising administering to the subject an effective amount of a compound of claim 35.
47. The method of claim 45 or 46, wherein the fibrotic condition is induced by radiation.
48. The method of claim 45 or 46, wherein the fibrotic condition is selected from the group consisting of scleroderma, lupus nephritis, connective tissue disease, wound healing, surgical scarring, spinal cord injury, CNS scarring, acute lung injury, idiopathic pulmonary fibrosis, radiation-induced pulmonary fibrosis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, acute lung injury, drug-induced lung injury, glomerulonephritis, diabetic nephropathy, hypertension-induced nephropathy, alimentary track or gastrointestinal fibrosis, renal fibrosis, hepatic or biliary fibrosis, liver cirrhosis, primary biliary cirrhosis, fatty liver disease, primary sclerosing cholangitis, restenosis, cardiac fibrosis, opthalmic scarring, fibrosclerosis, a fibrotic cancer, a fibroid, fibroma, a fibroadenoma, a fibrosarcoma, transplant arteriopathy, and keloid.
49. A method of inhibiting growth or metastasis of tumor cells or cancer in a subject, comprising administering to the subject an effective amount of a compound of claim 1.
50. A method of inhibiting growth or metastasis of tumor cells or cancer in a subject, comprising administering to the subject an effective amount of a compound of claim 35.
51. A method of treating a disease or disorder mediated by an overexpression of TGFjS, comprising administering to a subject in need of such treatment an effective amount of a compound of claim 1.
52. A method of treating a disease or disorder mediated by an overexpression of TGFjS, comprising administering to a subject in need of such treatment an effective amount of a compound of claim 35.
53. The method of claim 51 or 52, wherein the disease or disorder is selected from the group consisting of demyelination of neurons in multiple sclerosis, Alzheimer's disease, cerebral angiopathy, squamous cell carcinomas, multiple myeloma, melanoma, glioma, glioblastomas, leukemia, sarcomas, leiomyomas, mesothelioma, and carcinomas of the lung, breast, ovary, cervix, liver, biliary tract, gastrointestinal tract, pancreas, prostate, and head and neck.
EP05789340A 2004-08-31 2005-08-24 Pyrimidinylimidazoles as tgf-beta inhibitors Withdrawn EP1786802A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60604504P 2004-08-31 2004-08-31
PCT/US2005/030133 WO2006026306A1 (en) 2004-08-31 2005-08-24 Pyrimidinylimidazoles as tgf-beta inhibitors

Publications (1)

Publication Number Publication Date
EP1786802A1 true EP1786802A1 (en) 2007-05-23

Family

ID=35431931

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05789340A Withdrawn EP1786802A1 (en) 2004-08-31 2005-08-24 Pyrimidinylimidazoles as tgf-beta inhibitors

Country Status (6)

Country Link
EP (1) EP1786802A1 (en)
JP (1) JP2008511631A (en)
AU (1) AU2005280168A1 (en)
CA (1) CA2578630A1 (en)
TW (1) TW200621753A (en)
WO (1) WO2006026306A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044509A2 (en) * 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
MX2009003518A (en) 2006-10-03 2009-08-25 Genzyme Corp Use of tgf-î² antagonists to treat infants at risk of developing bronchopulmonary dysplasia.
JP2010526781A (en) * 2007-04-30 2010-08-05 アボット・ラボラトリーズ Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
JP2011509156A (en) 2008-01-08 2011-03-24 イェール ユニバーシティ Compositions and methods for promoting patency of vascular grafts
WO2009087224A1 (en) * 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
US8956868B2 (en) 2010-12-27 2015-02-17 Lsip, Llc Induced pluripotent stem cells produced with a connexin inhibitor and a TGF-β signaling inhibitor
WO2012167261A2 (en) 2011-06-03 2012-12-06 Yale University Compositions and methods for treating and preventing neointimal stenosis
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
AU2011379972B2 (en) 2011-10-26 2016-05-12 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
US10202356B2 (en) 2013-03-14 2019-02-12 Tolero Pharmaceuticals, Inc. JAK2 and ALK2 inhibitors and methods for their use
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
JP6363737B2 (en) * 2014-03-11 2018-07-25 ワン、イウェンＷＡＮＧ， Ｙｉ−Ｗｅｎ Pharmaceutical composition and method for reducing scar formation
UY36294A (en) 2014-09-12 2016-04-29 Novartis Ag COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS
CA3007631A1 (en) 2015-12-11 2017-06-15 Research Institute At Nationwide Children's Hospital Optimized patient specific non-linear tissue engineered vascular grafts
KR102341660B1 (en) 2016-09-19 2021-12-23 노파르티스 아게 A therapeutic combination comprising a RAF inhibitor and an ERK inhibitor
CN110494166B (en) 2017-05-02 2022-11-08 诺华股份有限公司 Combination therapy
MX2021000977A (en) 2018-07-26 2021-04-12 Sumitomo Pharma Oncology Inc Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same.
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
BR112021022335A2 (en) 2019-05-13 2021-12-28 Novartis Ag Crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
JP2023142282A (en) * 2022-03-24 2023-10-05 国立大学法人 熊本大学 Pharmaceutical composition for treating diseases that cause fibrosis
WO2024111626A1 (en) * 2022-11-25 2024-05-30 カルナバイオサイエンス株式会社 Novel thiazole derivative

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (en) * 2002-04-04 2005-02-16 Biogen Inc HETEROARILOS TRISUSTITUIDOS AND METHODS FOR ITS PRODUCTION AND USE OF THE SAME
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
AU2003263404A1 (en) * 2002-09-18 2004-04-08 Pfizer Products Inc. Novel imidazole compounds as transforming growth factor (tgf) inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006026306A1 *

Also Published As

Publication number Publication date
JP2008511631A (en) 2008-04-17
AU2005280168A1 (en) 2006-03-09
TW200621753A (en) 2006-07-01
WO2006026306A1 (en) 2006-03-09
CA2578630A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
AU2003228446B2 (en) Tri-substituted heteroaryls and methods of making and using the same
EP1786802A1 (en) Pyrimidinylimidazoles as tgf-beta inhibitors
US7691865B2 (en) Pyrazolopyridines and methods of making and using the same
US20060264440A1 (en) Pyrazoles and methods of making and using the same
US20100035918A1 (en) Imidazolone Compounds and Methods of Making and Using the Same
WO2009009059A1 (en) Spiro compounds as antagonists of tgf-beta
US20080171755A1 (en) Pyrimidinylpyrazoles as Tgf-Beta Inhibitors
US20100105714A1 (en) Furanone Compounds and Methods of Making and Using The Same
US20080319022A1 (en) 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070228

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOGEN IDEC MA INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SINGH, JUSWINDER

Inventor name: LEE, WEN-CHERNG

Inventor name: SUN, LIHONG

Inventor name: SHAN, FENG

Inventor name: CHUAQUI, CLAUDIO

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1103042

Country of ref document: HK

17Q First examination report despatched

Effective date: 20080929

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090210

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1103042

Country of ref document: HK